Track market-moving stories before they get noisy

Cover image via depositphotos.com Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

A technical failure on the XRP Ledger (XRPL) network that slowed transaction processing has turned into an open analysis of the protocol's architecture. David Schwartz, former Chief Technology Officer of Ripple and co-creator of the system, publicly named the blockchain's vulnerable points highlighted by the incident.

The problems began after the XRP Ledger Operations team recorded an anomaly: the network's ledgers started closing significantly slower than usual. While engineers searched for the cause of the delays, questions arose in the community about the reliability of the decentralized system. Users were concerned about whether the network could fail due to the overload of several key hubs. Schwartz stepped into the discussion to explain the real limits of XRPL's resilience.

You Might Also Like

HOT Stories

According to Schwartz's assessment, the XRP Ledger software is protected by a multi-layered security system. Nevertheless, in theory there are only two scenarios capable of completely paralyzing the entire network:

Mass infrastructure failure: a situation in which a huge number of validator servers around the world fail simultaneously. Such an outcome is possible only in the event of a global natural catastrophe, so developers consider it unlikely.

Consensus algorithm failure: an error in the very mechanism for reaching agreement between nodes, or the failure of another basic protocol function at the code level.

The recorded slowdown of rounds is direct evidence that the system's technological safety margins have decreased. Schwartz admitted that this is a marker that the network is either under a targeted attack or a hidden bug has been activated inside the code.

At the same time, the architect refuted rumors about the blockchain's vulnerability to single points of failure. The network is fully decentralized, so shutting down or overloading even a large hub (including his own node) has no effect on XRPL's overall operability and uptime.

How the creator of the network was left without logsThe main practical problem turned out to be the vulnerability of the network monitoring systems during peak loads. When consensus rounds slowed down, validators abruptly switched to maximum load. Schwartz's own node could not withstand the influx of requests, causing local RPC connections to hang in the CLOSE_WAIT state.

Official announcement of the XRP Ledger network slowdown, Source: XRP Ledger Operations / XBecause of this hang, Schwartz's internal monitoring system was unable to record and transmit diagnostic data at the most critical moment. As a result, the engineer had to reboot the server without understanding the exact cause of the failure.

During the discussion, it emerged that the hub of the XRPL co-creator was sending logs to an outdated test host of the XRP Ledger Foundation (XRPLF). 

You Might Also Like

Currently, the team of engineers and community operators is manually analyzing the surviving logs to isolate and completely eliminate the defect. Schwartz summarized that, despite the temporary reduction in safety margins, the team has no reason to panic. The developers are fully in control of the situation, and the code architecture has a sufficient technological reserve to keep the network operational.

Initial engineering program is leveraging IMPSA’s decades of nuclear experience to advance engineering and manufacturability of the KRONOS MMR™ design

New York, N.Y. and Mendoza, Argentina, Oct. 21, 2026 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) ("NANO" or “the Company"), a leading advanced nuclear micro modular reactor and technology company developing microreactors, nuclear fuel cycle capabilities and nuclear transportation solutions, today announced that it has entered into a Engineering Services Master Agreement (ESMA) with the U.S. subsidiary of IMPSA, one of Argentina's leading engineering and heavy-manufacturing companies, to support the engineering, design-for-manufacture and potential future fabrication of critical components for NANO Nuclear’s KRONOS MMR™ Energy System.

The three-year agreement establishes a framework for NANO Nuclear to utilize IMPSA's extensive experience in nuclear pressure vessels, ASME Section III manufacturing, welding, non-destructive examination, quality assurance and heavy-component fabrication as the KRONOS MMR™ design progresses toward manufacturing readiness.

The reactor pressure vessel is specifically identified as a principal reactor-component under evaluation by IMPSA. The parties have separately identified reactor cavity cooling systems, spent-fuel storage systems and additional reactor and transportation components as additional areas of potential collaboration.

Initial KRONOS MMR™ Engineering and Manufacturability Program

Under the ESMA, NANO and IMPSA are beginning with a dedicated KRONOS MMR™ Design Review and Assessment – Engineering Consulting and Manufacturability Feasibility Study. The initial program provides for an estimated six-month period, supported by a retainer. IMPSA's work is expected to include an independent review of KRONOS MMR™ components against applicable ASME Boiler and Pressure Vessel Code Section III requirements and the application of IMPSA's prior experience engineering and fabricating nuclear pressure vessels and other nuclear components.

The program aims to incorporate manufacturing expertise into the KRONOS MMR™ design process at an early stage, allowing the companies to identify potential fabrication constraints, inspection limitations, accessibility issues, supply-chain risks and potential design improvements ahead of future manufacturing. As required by NANO, the work may also extend to detailed engineering and fabrication drawings, code-compliant calculations, 3D models and other engineering deliverables.

Figure 1: NANO Nuclear Energy’s engineering team visits IMPSA’s manufacturing facility for a project kickoff meeting

"IMPSA has developed sophisticated nuclear engineering and manufacturing capabilities over many decades, and we see an opportunity to connect that expertise with the next generation of advanced nuclear projects," said Jay Yu, Founder and Chairman of NANO Nuclear Energy. "Our objective is to build NANO Nuclear with the capabilities needed to commercialize nuclear technology: reactor engineering, manufacturing, fuel, transportation and project execution. Our relationship with IMPSA can strengthen several of those areas at the same time while establishing an important industrial relationship between the United States and Argentina."

"Advanced reactors have to move from drawings and calculations to modular components that can be manufactured repeatedly, inspected, qualified and assembled," said James Walker, Chief Executive Officer of NANO Energy. "IMPSA brings more than four decades of nuclear engineering and manufacturing experience and particularly valuable expertise in nuclear pressure vessels and ASME Section III fabrication. Having that manufacturing knowledge applied to KRONOS at this stage is expected to identify constraints earlier, strengthen the design-for-manufacture process and build a much more direct pathway toward future component production."

The non-exclusive ESMA describes IMPSA as one of the few companies in Latin America certified with ASME N and ASME III N stamps, providing capabilities for the engineering and construction of Class 1 heavy nuclear components.

"This alliance represents a strategic opportunity for IMPSA and for the Argentine nuclear industry," said Jorge Salcedo Hernández, President of IMPSA. "With decades of experience manufacturing pressure vessels under ASME N-Stamp certification, IMPSA has established itself as one of the few suppliers capable of assessing the manufacturability of nuclear components at an early stage. Our goal is to enable NANO Nuclear to accelerate the KRONOS MMR™ manufacturing process, advancing toward safer and more efficient nuclear systems."

Future component fabrication, regional projects or other commercial activities beyond the initial engineering services will remain subject to the results of the engineering work, applicable regulatory requirements and, where required, additional work orders or definitive agreements between the relevant parties.

About IMPSA

IMPSA is a company with more than 115 years of experience across multiple industries, specializing in the design and manufacturing of major components for nuclear power plants and in providing engineering equipment and services that ensure high levels of safety and performance.

For more than 40 years, the company has played an active role in the Argentine nuclear industry’s most significant projects and challenges, combining expertise in manufacturing, engineering and technological innovation. It currently participates in the construction, refurbishment and modernization of nuclear facilities, as well as in the development and manufacturing of small modular reactors (SMRs).

About NANO Nuclear Energy, Inc.

NANO Nuclear Energy Inc. (NASDAQ: NNE) is a North American advanced technology-driven nuclear energy company seeking to become a commercially focused, diversified, and vertically integrated company across five business lines: (i) cutting edge portable and other microreactor technologies, (ii) nuclear fuel supply chain, (iii) nuclear fuel transportation, (iv) nuclear applications for space and (v) nuclear industry consulting services.

Led by a world-class nuclear engineering team, NANO Nuclear’s reactor products in development include the proprietary KRONOS MMR™ Energy System, a stationary high-temperature gas-cooled reactor that is in construction permit pre-application engagement U.S. Nuclear Regulatory Commission (NRC) in collaboration with University of Illinois Urbana-Champaign, “ZEUS”, a portable solid core battery reactor, and the space focused, portable LOKI MMR™, each representing advanced developments in clean energy solutions that are portable, on-demand capable, advanced nuclear microreactors.

Advanced Fuel Transportation Inc. (AFT), a NANO Nuclear subsidiary, bolstered by the May 2026 acquisition of Secured Transportation Services (STS), is led by former executives from the largest transportation company in the world and provides nuclear engineering and materials transport services in the U.S. and globally. Through NANO Nuclear, AFT is the exclusive licensee of a patented high-capacity HALEU fuel transportation basket developed by three major U.S. national nuclear laboratories and funded by the Department of Energy.

HALEU Energy Fuel Inc. (HEF), a NANO Nuclear subsidiary, is focusing on the future development of a domestic source for a High-Assay, Low-Enriched Uranium (HALEU) fuel fabrication pipeline for NANO Nuclear’s own microreactors as well as the broader advanced nuclear reactor industry.

NANO Nuclear Space Inc. (NNS), a NANO Nuclear subsidiary, is exploring the potential commercial applications of NANO Nuclear’s developing micronuclear reactor technology in space. NNS is focusing on applications such as the LOKI MMR™ system and other power systems for extraterrestrial projects and human sustaining environments, and potentially propulsion technology for long haul space missions. NNS’ initial focus will be on cis-lunar applications, referring to uses in the space region extending from Earth to the area surrounding the Moon's surface.

For more corporate information please visit: https://NanoNuclearEnergy.com/

For further NANO Nuclear information, please contact:

Email: [email protected]
Business Tel: (212) 634-9206

PLEASE FOLLOW OUR SOCIAL MEDIA PAGES HERE:

NANO Nuclear Energy LINKEDIN
NANO Nuclear Energy YOUTUBE
NANO Nuclear Energy X PLATFORM

Cautionary Note Regarding Forward Looking Statements

This news release and statements of NANO Nuclear’s management and collaborators in connection with this news release contain or may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “explore,” “plans”, “aim,” “goal,” “believes”, “potential”, “will”, “should”, “could”, “would” or “may” or derivations of these words and other words of similar meaning about the future. In this press release, forward-looking statements include those relating to the anticipated benefits to NANO Nuclear of the new Engineering Services Master Agreement with IMPSA described herein (which benefits may not be achieved) as well as NANO Nuclear’s operational plans and goals generally. These and other forward-looking statements are based on information available to us as of the date of this news release and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve significant known and unknown risks, uncertainties and other factors, which may be beyond our control. For NANO Nuclear, particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following: (i) risks related to our U.S. Department of Energy (“DOE”), U.S. Nuclear Regulatory Commission (“NRC”), Canadian Nuclear Safety Commission (“CNSC”) or related state or other U.S. or non-U.S nuclear licensing submissions, (ii) risks related the development of new or advanced technology and the acquisition of complementary technology or businesses, including difficulties with design and testing, cost overruns, regulatory delays, integration issues and the development of competitive technology, (iii) our ability to obtain and maintain key vendor, technology and customer contracts and the significant funding necessary to execute on our business plan, (iv) risks related to uncertainty regarding our ability to technologically develop and commercially deploy a competitive advanced nuclear reactor or other technology in the timelines we anticipate, if ever, (v) risks related to the impact of U.S. and non-U.S. government regulation, policies and licensing requirements, including by the DOE, and the NRC, including those associated with the recently enacted ADVANCE Act and the May 23, 2025 Executive Orders seeking to streamline nuclear regulation, and (vi) similar risks and uncertainties associated with the operating a developing business a highly regulated, competitive and rapidly evolving industry, including that our plans may change and we may use our cash on hand faster or in different ways than anticipated as our business requires. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement, and NANO Nuclear therefore encourages investors to review other factors that may affect future results in its filings with the SEC, which are available for review at www.sec.gov and at https://ir.nanonuclearenergy.com/financial-information/sec-filings. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.

NANO Nuclear Energy Inc.

NANO Nuclear Energy Inc. NANO Nuclear Energy’s engineering team visits IMPSA’s manufacturing facility for a project kickoff m...

Celestica (CLS - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this electronics manufacturing services company have returned -15.8%, compared to the Zacks S&P 500 composite's +0.7% change. During this period, the Zacks Electronics - Manufacturing Services industry, which Celestica falls in, has lost 9.1%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

Celestica is expected to post earnings of $3.01 per share for the current quarter, representing a year-over-year change of +90.5%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

The consensus earnings estimate of $11.32 for the current fiscal year indicates a year-over-year change of +87.1%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $19.01 indicates a change of +67.9% from what Celestica is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Celestica.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

For Celestica, the consensus sales estimate for the current quarter of $5.4 billion indicates a year-over-year change of +69.1%. For the current and next fiscal years, $20.35 billion and $31.99 billion estimates indicate +64.3% and +57.2% changes, respectively.

Last Reported Results and Surprise HistoryCelestica reported revenues of $4.7 billion in the last reported quarter, representing a year-over-year change of +62.4%. EPS of $2.54 for the same period compares with $1.39 a year ago.

Compared to the Zacks Consensus Estimate of $4.35 billion, the reported revenues represent a surprise of +8.08%. The EPS surprise was +10.92%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Celestica is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Celestica. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

OpenAI will make its frontier artificial intelligence models and Codex coding agent available through Google Cloud in the coming weeks, the companies said on Wednesday, deepening ties ​between two rivals and underscoring how major cloud providers are becoming key ‌distributors of top AI models.

The partnership will bring OpenAI's latest models such as GPT-6 Astra to Google Cloud's Model Garden. It will allow customers to buy them through Google Cloud Marketplace and use existing cloud spending ​commitments for the purchases, according to a company blog post, as OpenAI tries ​to sell its models to more enterprise customers.

It will also allow customers in ⁠regulated industries to access OpenAI models through Google Cloud's access controls, data governance tools and ​infrastructure to build so-called agentic AI workflows.

Alphabet's (GOOGL.O)
Google has become the latest major hyperscaler to offer OpenAI ​models to its customers, after OpenAI’s exclusive distribution arrangement with Microsoft (MSFT.O)
expired in April.

OpenAI has since expanded distribution to Amazon Web Services (AMZN.O) and now to Google Cloud, each a major hyperscaler vying for AI market share.

The deal adds ​another layer to an increasingly complex relationship between OpenAI and Google, which compete in core ​AI products and search even as the economics of building and deploying large models push them toward ‌cooperation.

Google has ⁠moved to position its cloud unit as a neutral platform offering customers a broader choice of models, after it struck a cloud deal with OpenAI to offer it more computing capacity last year.

For Google Cloud, adding OpenAI's models strengthens a strategy of offering customers a wider ​range of third-party models ​rather than relying only ⁠on its own.

Thomas Kurian, chief executive of Google Cloud, has told Reuters in a previous interview that the Google cloud platform is an ​open platform and it welcomes any model popular with developers in ​it.

The arrangement also ⁠fits a broader industry shift in which hyperscalers are becoming the main commercial channels for frontier AI labs. Cloud providers usually take a cut from sales through its platform.

Anthropic, an OpenAI rival ⁠backed ​by Amazon and Google, has seen 47% of its 2025 ​revenue coming from cloud providers Amazon and Google's cloud platforms, according to its IPO filing reviewed by Reuters.

Ken Griffin spent most of 2026 dismissing AI hype, then watched agentic tools collapse weeks of Citadel research into hours. Now he thinks a bubble is forming, and his reasoning explains why the market barely flinched at the word.

Ken Griffin changed his mind about artificial intelligence more than once in 2026. On October 20, 2026, at Citadel’s annual Future of Global Markets Conference in New York, the Citadel founder and CEO said investors are “almost certainly” in an AI bubble.

The market barely responded. After the close, NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) ended at $216.47, off 0.29%, before climbing 2.12% to $221.06 by 7:59 p.m. ET in after-hours trading. The Invesco QQQ Trust (NASDAQ:QQQ) slid 0.10% to $717.63. That calm looks reasonable once you read past the word bubble.

Griffin Ties Bubbles to Lasting Economic Change Griffin tied bubbles to real economic change: “Any radical transformation of our economy is generally intertwined with a bubble.”

He said the companies that make it through “are the market leaders for decades to come.” Remembering the dot-com era, he added, “I just wish I’d kept my Amazon stock in that moment.”

Money tends to arrive before the profits do, and while most new entrants fail, a few survivors keep growing for a generation.

Mixed AI Payoffs Would Reach Chipmakers First His more pointed warning was about returns. “Corporate America has been very uneven in its ability to extract value from its AI models,” he said. He described finance teams reviewing bills from Anthropic and OpenAI and concluding, “Okay, we need to think about how to make sure we’re getting productivity out of this.”

That problem flows straight to Nvidia. If buyers cannot show a payoff, cloud budgets slow and chip orders shrink. Nvidia’s supply commitments climbed to $279 billion, mostly memory for its Vera Rubin systems, so any pause in spending would cost it more.

Over 2026, Griffin went from dismissive at Davos in January to “unsettled” by AI’s abilities at Stanford’s business school in May. Griffin said agentic tools (software that works through multistep tasks by itself) cut certain Citadel research from 6-8 weeks to 2-3 hours. “You’re seeing the threat to white-collar jobs playing out,” he said, adding that he also expects “a golden era for entrepreneurs.”

How Much Froth Has Already Left Nvidia and QQQ Nvidia has a $5.23 trillion market value and is up 18.81% over the past year. Shares closed about 11% below their 52-week high of $243.37, and the 52-week low sits at $164.27.

QQQ is up 16.82% year-to-date, with a one-year total return of 19.39%. It sits about 6% under its $762.86 high and well above its $555.60 low. Nvidia made up about 7.6% of the fund’s net assets as of June 30, 2026.

Those pullbacks have taken some excess out, but Nvidia still trades at 44 times trailing earnings. In a separate view, Citadel Securities strategist Scott Rubner called the November 3, 2026 midterms a “clearing event for risk” and expects AI stocks to lead the market again after the vote.

What the Bull and Bear Cases Mean for AI Stocks The bull case comes from Griffin himself: bubbles produce the decade’s leaders. Nvidia’s latest quarter backs that up, with revenue of $96.22 billion, up 105.8%, and a net margin of 55.60%.

The bear case centers on spending. If companies keep struggling to turn AI bills into productivity, orders could slow even while the technology keeps improving.

Over a long horizon, the bull case looks stronger. Doubts about spending usually show up first as slower growth, and Nvidia’s margins give it room to absorb that. QQQ offers broader exposure than a single stock, because it holds the leaders Griffin describes without tying results to one company. The expansion also runs well beyond the chipmakers (we featured seven of the power, cooling, and networking suppliers behind the data centers in a free report), which is part of why diversified exposure holds up even if any one name stalls.

The test to check is Nvidia’s earnings report on November 17. Results at or above its third-quarter guidance of $108.0 billion would support the bull case. A miss blamed on customer spending would mean the payoff problem Griffin described has reached the supplier.

Contact [email protected] for any questions or corrections.

Diversify Advisory Services LLC grew its stake in Netflix, Inc. (NASDAQ:NFLX – Free Report) by 14.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 203,913 shares of the Internet television network’s stock after purchasing an additional 26,365 shares during the period. Diversify Advisory Services LLC’s holdings in Netflix were worth $14,806,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Merkkuri Wealth Advisors LLC bought a new position in Netflix in the 1st quarter valued at approximately $31,000. Bayban grew its stake in shares of Netflix by 400.0% during the first quarter. Bayban now owns 350 shares of the Internet television network’s stock worth $34,000 after buying an additional 280 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd bought a new stake in shares of Netflix during the second quarter worth $26,000. Compound Global Advisors LLC bought a new stake in shares of Netflix during the second quarter worth $29,000. Finally, Burnham & Co LLC acquired a new position in shares of Netflix during the second quarter worth $29,000. 80.93% of the stock is owned by institutional investors.

Insiders Place Their Bets In other Netflix news, CEO Gregory K. Peters sold 27,312 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $73.54, for a total transaction of $2,008,524.48. Following the completion of the transaction, the chief executive officer owned 120,931 shares in the company, valued at approximately $8,893,265.74. This trade represents a 18.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Theodore A. Sarandos sold 27,312 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $73.35, for a total transaction of $2,003,335.20. Following the completion of the transaction, the chief executive officer owned 178,954 shares in the company, valued at $13,126,275.90. This trade represents a 13.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 179,045 shares of company stock valued at $13,132,194 over the last three months. Insiders own 1.24% of the company’s stock.

Netflix Stock Down 1.7% Shares of NFLX opened at $68.69 on Wednesday. The stock’s 50-day moving average price is $74.92 and its two-hundred day moving average price is $80.20. Netflix, Inc. has a 12 month low of $65.08 and a 12 month high of $124.86. The company has a market capitalization of $286.02 billion, a PE ratio of 21.62, a PEG ratio of 0.99 and a beta of 1.62. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. Netflix (NASDAQ:NFLX – Get Free Report) last issued its quarterly earnings results on Tuesday, October 20th. The Internet television network reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.05. The company had revenue of $12.87 billion during the quarter, compared to analysts’ expectations of $12.87 billion. Netflix had a return on equity of 40.02% and a net margin of 28.22%. The business’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.59 earnings per share. On average, analysts anticipate that Netflix, Inc. will post 3.59 EPS for the current year.

Netflix News Summary Here are the key news stories impacting Netflix this week:

Positive Sentiment: Netflix exceeded third-quarter profit expectations, reporting diluted EPS of $0.87 versus the $0.82 consensus estimate. Revenue reached $12.87 billion, operating income rose 37% year over year to $4.46 billion, and operating margin expanded to 34.6%. Netflix Q3 earnings beat Positive Sentiment: Management cited pricing power, controlled churn and strong profitability, while Netflix repurchased approximately $4.8 billion of stock during the quarter. These factors support earnings per share and shareholder returns. Netflix Q3 financial results Positive Sentiment: Some analysts view the sharp decline in the stock and its valuation as creating an attractive entry point if management can restore viewership growth and improve content execution. Netflix is cheap again Neutral Sentiment: Netflix is cutting roughly 1,000 jobs and reorganizing its creative leadership, including changes involving film and content executives. Co-CEO Greg Peters described the layoffs as a difficult tradeoff intended to redirect investment toward longer-term growth, but the restructuring may create near-term execution risk. Netflix layoffs and long-term growth Negative Sentiment: The main pressure on NFLX is its fourth-quarter outlook: revenue is projected at approximately $13.4 billion, below Wall Street expectations, with operating margin expected to fall to 26% as restructuring costs weigh on results. Netflix weak fourth-quarter forecast Negative Sentiment: Netflix reduced its 2026 advertising-revenue forecast to approximately $2.7 billion from $3 billion because advertising-product rollouts are progressing more slowly than expected. The shortfall undermines a key growth narrative. Netflix cuts advertising forecast Negative Sentiment: Revenue growth is expected to slow for a fourth consecutive quarter, while stagnant viewership—particularly in the United States and Canada—and intensifying competition are raising concerns about Netflix’s ability to keep audiences engaged. Netflix viewership and competition concerns Negative Sentiment: The company also lowered its 2026 free-cash-flow outlook to about $12 billion from $12.5 billion, adding to investor concerns that forward momentum is weakening despite the quarterly earnings beat. Analysts Set New Price Targets A number of brokerages have recently commented on NFLX. KeyCorp dropped their price target on Netflix from $92.00 to $85.00 and set an “overweight” rating for the company in a research note on Tuesday, October 13th. Rosenblatt Securities reissued a “neutral” rating and set a $75.00 price objective on shares of Netflix in a report on Friday, October 16th. BMO Capital Markets restated an “outperform” rating and set a $125.00 price objective (down from $135.00) on shares of Netflix in a research report on Friday. Bank of America lowered their target price on Netflix from $125.00 to $105.00 and set a “buy” rating for the company in a report on Friday, July 17th. Finally, Loop Capital lowered their target price on Netflix from $115.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 24th. Three investment analysts have rated the stock with a Strong Buy rating, thirty-five have assigned a Buy rating, sixteen have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $93.38.

Get Our Latest Research Report on Netflix

Netflix Profile (Free Report)

Netflix, Inc (NASDAQ:NFLX) is a global entertainment company that provides subscription-based streaming services. Its platform offers a broad selection of television series, films, documentaries, stand-up specials and other programming, including content produced by Netflix and licensed from third-party studios and creators.

The company also develops and distributes original productions under the Netflix brand and has expanded into additional entertainment offerings, including mobile and cloud-based games in select markets and live programming.

Featured Articles Five stocks we like better than Netflix Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding NFLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Netflix, Inc. (NASDAQ:NFLX – Free Report).

Receive News & Ratings for Netflix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Netflix and related companies with MarketBeat.com's FREE daily email newsletter.

Visa Inc. (NYSE:V – Get Free Report) shares hit a new 52-week high on Wednesday. The company traded as high as $408.59 and last traded at $406.57, with a volume of 6,703,827 shares trading hands. The stock had previously closed at $402.92.

Visa News Roundup Here are the key news stories impacting Visa this week:

Positive Sentiment: AI-driven business payments: Visa, BILL and Billtrust launched a live pilot allowing trusted AI agents to complete approved invoice payments between buyers and suppliers. The initiative could help Visa capture a larger share of business-to-business payments and replace manual processes, checks and legacy payment methods. Visa, BILL and Billtrust Launch First Live Pilot Positive Sentiment: Crypto and stablecoin expansion: Visa partnered with Mesh to enable users of participating wallets to spend crypto and stablecoin balances at more than 175 million Visa-accepting merchant locations, without a separate crypto card or manual cash-out. The arrangement could generate additional payment volume while allowing merchants to use existing Visa infrastructure. How Is Visa Turning Crypto And AI Payments Into Real World Use? Positive Sentiment: Broader commercial and international reach: Visa expanded its U.K. online merchant presence through Barclaycard’s Unified Checkout and enabled eligible fintechs to offer Visa corporate cards in more than 40 countries. These partnerships support digital-wallet adoption and cross-border payment growth. Visa Expands U.K. Merchant Reach Neutral Sentiment: Upcoming earnings catalyst: Wall Street expects Visa to report earnings growth in its upcoming quarterly release, with investors also watching for guidance and a potential annual dividend increase. The company’s prior quarter delivered revenue and earnings above consensus estimates. Visa Reports Next Week Negative Sentiment: Valuation and execution risks: Visa trades at a premium earnings multiple near all-time highs, leaving less room for an earnings or guidance disappointment. The Mesh rollout has not yet disclosed all participating wallets or launch timing, while regulatory scrutiny, merchant resistance to interchange changes and potential U.S. credit-card legislation could pressure future growth. Analyst Upgrades and Downgrades V has been the subject of a number of research analyst reports. Clear Str raised shares of Visa to a “strong-buy” rating in a report on Thursday, July 16th. Robert W. Baird boosted their price objective on shares of Visa from $420.00 to $430.00 and gave the stock an “outperform” rating in a report on Monday, October 12th. Daiwa Securities Group lifted their target price on shares of Visa from $375.00 to $422.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. Barclays started coverage on Visa in a research note on Tuesday, July 7th. They issued an “overweight” rating and a $420.00 target price for the company. Finally, JPMorgan Chase & Co. boosted their price objective on Visa from $400.00 to $450.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Three analysts have rated the stock with a Strong Buy rating and thirty-four have assigned a Buy rating to the company. Based on data from MarketBeat, Visa has a consensus rating of “Buy” and an average price target of $426.12.

Check Out Our Latest Stock Report on Visa Visa Stock Performance The company has a quick ratio of 0.99, a current ratio of 0.99 and a debt-to-equity ratio of 0.60. The firm has a market cap of $725.50 billion, a P/E ratio of 34.57, a P/E/G ratio of 1.89 and a beta of 0.77. The business has a fifty day simple moving average of $374.46 and a 200-day simple moving average of $348.09.

Visa (NYSE:V – Get Free Report) last released its earnings results on Tuesday, July 28th. The credit-card processor reported $3.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.23 by $0.09. The firm had revenue of $11.63 billion during the quarter, compared to analyst estimates of $11.40 billion. Visa had a net margin of 50.78% and a return on equity of 67.68%. The business’s revenue was up 14.4% on a year-over-year basis. During the same period last year, the business earned $2.98 earnings per share. On average, sell-side analysts predict that Visa Inc. will post 13.22 EPS for the current fiscal year.

Visa Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Investors of record on Tuesday, August 11th were given a dividend of $0.67 per share. The ex-dividend date of this dividend was Tuesday, August 11th. This represents a $2.68 annualized dividend and a dividend yield of 0.7%. Visa’s dividend payout ratio (DPR) is 22.79%.

Insider Transactions at Visa In related news, insider Tullier Mahon sold 57,272 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $364.97, for a total transaction of $20,902,561.84. Following the transaction, the insider owned 49,662 shares in the company, valued at $18,125,140.14. This represents a 53.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan Mcinerney sold 5,875 shares of Visa stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $358.81, for a total value of $2,108,008.75. Following the completion of the sale, the chief executive officer directly owned 15,174 shares of the company’s stock, valued at $5,444,582.94. The trade was a 27.91% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 78,792 shares of company stock worth $28,863,319 over the last three months. 0.12% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows Several institutional investors have recently made changes to their positions in V. Philadelphia Investment Partners LLC purchased a new stake in shares of Visa during the 2nd quarter worth about $29,000. Virtus Advisers LLC bought a new stake in shares of Visa in the 2nd quarter valued at approximately $33,000. Robinswood Financial LLC bought a new stake in shares of Visa in the 1st quarter valued at approximately $35,000. Portfolio Resources Advisor Group Inc. acquired a new position in Visa in the third quarter worth approximately $35,000. Finally, Midwest Capital Advisors LLC acquired a new position in Visa in the first quarter worth approximately $37,000. Institutional investors own 82.15% of the company’s stock.

Visa Company Profile (Get Free Report)

Visa Inc (NYSE: V) is a global payments technology company that facilitates electronic payments between consumers, businesses, financial institutions and governments. Through its VisaNet network, the company authorizes, clears and settles transactions made with Visa-branded credit, debit and prepaid cards, while generally not issuing cards, extending credit or setting cardholder account terms.

Visa provides payment products and services for consumer, commercial and government payments, as well as digital commerce and money movement.

Featured Articles Five stocks we like better than Visa Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Receive News & Ratings for Visa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Visa and related companies with MarketBeat.com's FREE daily email newsletter.

United Airlines is set to open its biggest airport lounge this week, which it says is the largest in the Americas, as airlines continue to plow money into the facilities for high-spending customers.

The 54,000-square-foot lounge is opening Thursday at George Bush Intercontinental Airport's Terminal B in Houston, part of an overhaul of the facility that includes 22 gates for mainline aircraft.

The airport, with more than 500 departures a day, is United's main connecting hub for flights to and from Latin America.

The new club can seat 800 people and features an outdoor terrace for plane-spotting as well as two full-service bars and buffets.

The lounge, part of United's $2.6 billion investment at the airport's Terminal B, shows how airlines are putting more money into larger spaces for premium-travel demand to attract the growing ranks of elite frequent flyers, co-branded credit card holders and customers just willing to spend more to fly.

American Airlines earlier this month said it is planning its largest-ever lounge at its Charlotte Douglas International Airport hub in North Carolina. Delta Air Lines has expanded both its popular Delta Sky Clubs and its top-tier Delta One Lounges.

Southwest Airlines is building its first-ever network of airport lounges, which are tied to its credit card partner, Chase. Last week, the carrier unveiled mock-ups of the lounges, which it is calling Icon. And JetBlue Airways opened lounges in New York and Boston in the past year.

Read more CNBC airline newsWhy airfare could rise even more, but airline profits won’tBudget airline king Bill Franke warms to premium upgradesCompanies spurn airlines’ cheapest business class ticketsUnited’s next decision: What to do with all those Boeing 737 Max 10 seats it ordered years agoRecord heat, crowds drive offseason boom in international travel

Analysts with JPMorgan Chase upgraded Intel (INTC -0.70%) to neutral from underweight on Monday, Oct. 19, citing growing agentic artificial intelligence (AI) workloads and tight supplies of advanced chips. The chipmaker's stock gained around 2% that day, ending at $92.03.

Even after that bounce, shares are around 35% under their record close of $140.94 on June 22. And most of the drop has happened lately. The stock still closed above $127 as late as Sept. 24.

Sure, an upgrade to neutral isn't a call to buy, and I wouldn't buy or sell a stock based on an analyst's rating anyway. What matters more is how much investors now pay for what Intel earns. And by that measure, the stock has gotten far cheaper than its 35% drop suggests.

Image source: Intel.

Intel's earnings have nearly doubledWhen Intel set its record in June, its four most recently reported quarters came to non-GAAP (adjusted) earnings per share of just $0.57. That figure included a loss of $0.10 a share in the second quarter of 2025.

At $140.94, then, investors were paying almost 250 times Intel's adjusted earnings for the previous four quarters.

Intel's second-quarter results, released in July, changed that. Revenue rose 25% year over year to $16.1 billion, accelerating sharply from 7% growth in the first quarter and a 4% fall in the fourth quarter of 2025. And adjusted earnings per share climbed to $0.42, up from $0.15 in the fourth quarter of 2025 and $0.29 in the first quarter of 2026.

Combined, the past four reported quarters now total $1.09 a share in adjusted earnings -- nearly double the June number.

At around $92 as I write, Intel trades at about 84 times these earnings. It's still a steep price-to-earnings ratio. But it's around a third of where the ratio was at the record, even though the share price fell only about 35%. In other words, rising profits did more to cut the stock's price-to-earnings ratio than the falling share price did.

Intel's GAAP results look much worse. On that basis, the company lost $2.16 a share for the second quarter. But a non-cash charge of $2.45 a share more than accounted for the loss. The charge is linked to Intel stock held in escrow for the U.S. government under its CHIPS Act deal, so I'm leaning on the adjusted numbers here.

A step backThe next step is a smaller one, though. For the third quarter, management's guidance calls for $0.38 a share in adjusted earnings. This would be up 65% from $0.23 for the third quarter of 2025, but down from the second quarter's $0.42.

Revenue growth may slow, too. The midpoint of Intel's guidance range from $15.8 billion to $16.8 billion implies growth of around 19% year over year, after 25% for the second quarter.

If Intel earned $0.38 a share every quarter over a year, it'd make around $1.52. At around $92 a share, the stock would cost about 60 times that annual pace of earnings.

Demand for AI computing doesn't look like the issue.

"AI-driven compute continues to strengthen, and to support expected growth this year and next across products and foundry, we are meaningfully increasing our investments in equipment, clean room space, and substrates," CFO Dave Zinsner said in Intel's second-quarter earnings release.

Turning that demand into steadily rising earnings per share is what Intel still needs to prove. And the third-quarter guidance suggests the climb might not continue every quarter.

INTC Intel$91.05-$0.64 (-0.70%)

NASDAQ · As of 9:54 AM ET 10/21/26

Is the drop big enough?Based on expected earnings for 2027, Intel trades at around 44 times earnings. That price-to-earnings ratio arguably assumes Intel's profits can keep climbing well past the third quarter's pace. Intel posts third-quarter results on Thursday, Oct. 29, which might show whether the $0.38 forecast was cautious or the start of a flatter stretch.

Does the 35% drop make Intel stock a buy? I don't think so yet. The drop, plus a far stronger second quarter, has moved the price a lot closer to what Intel earns. But at around 84 times adjusted earnings in the past four quarters, the stock still prices in lots of growth that hasn't come yet.

I'd want to see adjusted earnings per share climb back above the second quarter's $0.42 before considering the stock at this price.

Oracle Health and Oracle Fusion Cloud Applications will help bring data together, streamline work, and support a more connected patient experience

, /PRNewswire/ -- Southwest General, a private, not-for-profit, acute care hospital in Middleburg Heights, Ohio, is expanding its relationship with Oracle. Building on its use of Oracle Health Foundation EHR and the recent integration of Oracle Health AI Agents, clinical note capabilities, to help automate routine administrative tasks and give physicians more time with patients, Southwest General is adopting Oracle Health Patient Accounting, Oracle Health Data Intelligence, and Oracle Fusion Cloud Applications. These applications will help unify clinical, financial, and operational information, simplify workflows, and support informed care decisions across the organization.

As an independent community-focused health center, Southwest General is working to alleviate administrative complexity created by disconnected financial, operational, and health information systems. By expanding its use of Oracle technology across the enterprise, Southwest General will build an integrated environment that helps its team access the right information when and where it needs it, reduce manual processes, and spend more time supporting patients throughout their healthcare journeys.

"At Southwest General, we are taking control of our digital transformation to build an environment that works better for our patients and for the people who care for them," said Jae Zayed, chief digital and information officer, Southwest General. "With Oracle, we are bringing our clinical, financial, and operational systems into a shared environment to better equip clinicians and staff with the information and tools they need to focus on what matters most—delivering high-quality care. This investment will help us improve the experience for our team and for the patients and families who rely on us."

Southwest General will use Oracle Health Patient Accounting to create a comprehensive view of key financial information for its revenue cycle team. By bringing billing, payments, claims, and account information into one system, Oracle Health Patient Accounting can help reduce manual work, support accurate billing and faster payment processing, and make it easier to address patient questions. Streamlining these processes can improve the experience for both patients and staff while supporting stronger revenue operations.

Oracle Health Data Intelligence will help Southwest General bring health data together in a central environment, making relevant patient information easier for its care team to access. With a more complete view of information they need, clinicians can make more informed care decisions, better coordinate care, and identify opportunities to improve the patient experience.

To complement these solutions, Southwest General plans to adopt the full Oracle Fusion Applications suite including: Oracle Fusion Cloud Enterprise Resource Planning (ERP), Oracle Fusion Cloud Enterprise Performance Management (EPM), Oracle Fusion Cloud Human Capital Management (HCM), Oracle Fusion Cloud Supply Chain & Manufacturing (SCM), and Oracle Fusion Cloud Customer Experience (CX). Together, these AI-powered enterprise applications will help Southwest General standardize processes, improve visibility into enterprise performance, and establish a scalable foundation for continued innovation.

"Our community deserves care and service supported by modern capabilities that help us meet today's healthcare challenges," said Darrell Lentz, chief financial officer, Southwest General. "Oracle is giving us the platform and unified data environment to leapfrog years ahead of industry leaders, helping our team make more contextually aware care decisions, manage the revenue cycle with greater confidence, and operate with greater agility. This is about raising the bar for the care and service we provide to our community."

"Healthcare organizations need connected systems that make it easy for people to do their best work and focus on the people they serve," said Seema Verma, executive vice president and general manager, Oracle Health and Life Sciences. "By connecting care delivery, revenue cycle, and enterprise operations with Oracle, Southwest General is equipping its team to work from a more complete picture and helping create a more coordinated, responsive experience for its community. Oracle is proud to support its continued leadership and innovation."

To learn more about how Oracle Health is helping transform healthcare, visit www.oracle.com/health.

About Southwest General
Southwest General Health Center is a private, not-for-profit, 368-bed acute care hospital located in Middleburg Heights, Ohio. Founded in 1920, Southwest General has a long-standing reputation for clinical excellence, compassionate care, and personalized service. The hospital is home to nationally recognized physicians and offers comprehensive, high-quality care supported by advanced technology and a commitment to continuous improvement. Dedicated to serving the communities southwest of Greater Cleveland, Southwest General partners with patients and families to deliver exceptional care close to home.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit www.oracle.com.

About Oracle Fusion Cloud Applications
Oracle Fusion Cloud Applications provide an integrated suite of AI-powered cloud applications that enable organizations to execute faster, make smarter decisions, and lower costs. Oracle Fusion Applications include:

Oracle Fusion Cloud Enterprise Resource Planning (ERP): Provides a comprehensive suite of AI-powered finance and operations applications that help organizations increase productivity, reduce costs, expand insights, improve decision-making, and enhance controls. Oracle Fusion Cloud Human Capital Management (HCM): Provides a unified AI-powered HR platform that connects all people-related processes and data to help organizations automate tasks throughout the employee lifecycle, improve the employee experience, and give HR leaders actionable workforce insights. Oracle Fusion Cloud Supply Chain & Manufacturing (SCM): Provides a unified AI-powered platform that integrates supply chain and operations processes and helps organizations enhance resilience and quickly adapt to market changes. Oracle Fusion Cloud Customer Experience (CX): Provides a suite of AI-powered applications that help organizations manage marketing, sales, and service processes to win business, build stronger customer relationships, and improve customer experiences. Trademarks
Oracle, Java, MySQL, and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company, ushering in the new era of cloud computing.

SOURCE Oracle

Moody's (MCO - Free Report) came out with quarterly earnings of $4.14 per share, missing the Zacks Consensus Estimate of $4.25 per share. This compares to earnings of $3.92 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of -2.59%. A quarter ago, it was expected that this credit ratings agency would post earnings of $4.24 per share when it actually produced earnings of $4.68, delivering a surprise of +10.38%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Moody's, which belongs to the Zacks Financial - Miscellaneous Services industry, posted revenues of $2.02 billion for the quarter ended September 2026, missing the Zacks Consensus Estimate by 2.02%. This compares to year-ago revenues of $2.01 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Moody's shares have lost about 7% since the beginning of the year versus the S&P 500's gain of 12.7%.

What's Next for Moody's?While Moody's has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Moody's was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.62 on $1.93 billion in revenues for the coming quarter and $16.92 on $8.28 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Financial - Miscellaneous Services is currently in the bottom 28% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Antalpha Platform Holding Company (ANTA - Free Report) , has yet to report results for the quarter ended September 2026.

This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of -64.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Antalpha Platform Holding Company's revenues are expected to be $11.45 million, down 45.6% from the year-ago quarter.

EBay (EBAY.O) will lay off about 9% of its workforce as the online marketplace ​looks to simplify operations and shift resources to its fastest-growing ‌areas, CEO Jamie Iannone told staff in a memo that was reviewed by Reuters.

A spokesperson for eBay confirmed the layoffs to Reuters on Wednesday.

The move will eliminate around ​1,100 jobs, based on the 12,300 employees eBay had at ​the end of last year. The company also let go ⁠about 6% of its workforce, or 800 employees, in February as part of ​efforts to streamline operations.

EBay has set itself apart from rivals by pushing ​into authenticated luxury goods, collectibles and refurbished products, which draw enthusiasts willing to pay more for valuable items. That has helped its shares rise nearly 40% this year, ​outperforming the benchmark S&P 500's around 12% gain.

"Our strategy is working," ​Iannone said in the memo, adding that "continuing to capture the significant opportunity ahead requires ‌us to ⁠make thoughtful choices about where we focus and invest."

He said affected staff would be informed in the coming days.

Shares of eBay were down 1.8% in premarket trading.

The company has this year also benefited from its $1.4 billion ​deal for fashion ​resale platform Depop, ⁠which expanded its reach among younger consumers and strengthened its position in the growing re-commerce market.

That helped eBay ​forecast third-quarter revenue above Wall Street estimates when it ​last posted ⁠results, in August. The company is slated to report latest earnings next week.

Those efforts have also caught the eye of GameStop CEO Ryan Cohen, who ⁠made ​an unsolicited $56 billion bid for the much ​larger eBay in May. EBay had rejected the offer, saying that it was "neither credible nor attractive."

Pinterest (PINS - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Over the past month, shares of this digital pinboard and shopping tool company have returned +25%, compared to the Zacks S&P 500 composite's +0.7% change. During this period, the Zacks Internet - Software industry, which Pinterest falls in, has gained 1.9%. The key question now is: What could be the stock's future direction?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Pinterest is expected to post earnings of $0.50 per share, indicating a change of +31.6% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $2.06 for the current fiscal year indicates a year-over-year change of +28.8%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $2.35 indicates a change of +14.2% from what Pinterest is expected to report a year ago. Over the past month, the estimate has remained unchanged.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Pinterest is rated Zacks Rank #4 (Sell).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Pinterest, the consensus sales estimate of $1.2 billion for the current quarter points to a year-over-year change of +14.4%. The $4.89 billion and $5.54 billion estimates for the current and next fiscal years indicate changes of +15.9% and +13.2%, respectively.

Last Reported Results and Surprise HistoryPinterest reported revenues of $1.18 billion in the last reported quarter, representing a year-over-year change of +18.2%. EPS of $0.43 for the same period compares with $0.33 a year ago.

Compared to the Zacks Consensus Estimate of $1.15 billion, the reported revenues represent a surprise of +2.39%. The EPS surprise was +19.44%.

Over the last four quarters, Pinterest surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Pinterest is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Pinterest. However, its Zacks Rank #4 does suggest that it may underperform the broader market in the near term.

Net Worth Advisory Group grew its position in Micron Technology, Inc. (NASDAQ:MU – Free Report) by 253.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,552 shares of the semiconductor manufacturer’s stock after acquiring an additional 1,113 shares during the period. Net Worth Advisory Group’s holdings in Micron Technology were worth $1,703,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Denali Advisors LLC bought a new position in Micron Technology during the 2nd quarter worth approximately $7,364,000. Castleark Management LLC bought a new stake in Micron Technology during the 1st quarter valued at $3,709,000. Oppenheimer & Co. Inc. raised its holdings in shares of Micron Technology by 16.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 48,520 shares of the semiconductor manufacturer’s stock worth $56,006,000 after acquiring an additional 6,702 shares during the last quarter. Legacy Wealth Management LLC MS raised its position in Micron Technology by 73.3% in the 2nd quarter. Legacy Wealth Management LLC MS now owns 3,544 shares of the semiconductor manufacturer’s stock valued at $4,091,000 after buying an additional 1,499 shares during the last quarter. Finally, Franklin Street Advisors Inc. NC lifted its position in shares of Micron Technology by 2,461.4% during the second quarter. Franklin Street Advisors Inc. NC now owns 37,141 shares of the semiconductor manufacturer’s stock valued at $42,871,000 after purchasing an additional 35,691 shares in the last quarter. 80.84% of the stock is owned by institutional investors and hedge funds.

Micron Technology News Roundup Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: Micron announced funding for Indium Corporation’s critical-minerals and high-purity materials processing expansion in New York. The investment, part of Micron’s planned U.S. supply-chain spending of up to $3 billion, is intended to improve access to materials needed for advanced memory production and reduce exposure to overseas supply disruptions. Micron Invests in New York Critical Minerals Processing With Indium Corporation Positive Sentiment: Bullish analysts continue to point to tight memory supply, rising contract prices, strong AI-related demand and a potential share repurchase program. Recent results and guidance also showed substantial revenue and earnings growth, supporting the view that Micron’s memory upcycle could extend through 2027 and beyond. Micron Stock Moves Higher: What’s Going On? Positive Sentiment: Some investors view MU as attractively valued relative to its earnings potential, with Wall Street highlighting its strong September-quarter performance, elevated memory prices and multiyear customer commitments as reasons for further upside. The Best Trillion-Dollar Stock to Buy Right Now, According to Wall Street Neutral Sentiment: Micron is scheduled to host a technology webinar on October 21, which could provide additional details on its AI-memory roadmap, manufacturing plans and demand outlook. Micron to Host Technology Webinar on Oct. 21 Negative Sentiment: A union at Micron’s Taoyuan facility in Taiwan plans to strike on October 22 over a bonus dispute. Because Taiwan is central to Micron’s DRAM production, investors are concerned about potential disruption, costs or shipment delays. Micron Union in Taiwan to Launch Strike Negative Sentiment: Memory stocks remain under pressure after a broader technology selloff revived fears that AI infrastructure spending and related valuations may be unsustainable. Investors are also questioning how long Micron’s unusually high profits can last as new capacity comes online and rivals respond. Micron Stock Falls Amid Three Warning Signals Negative Sentiment: China’s CXMT is progressing toward server-memory production, raising longer-term competitive and pricing concerns for Micron, particularly if Chinese suppliers expand despite export restrictions. Intel Versus Micron: Exposure to CXMT Insiders Place Their Bets In other news, EVP Sumit Sadana sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $934.29, for a total transaction of $14,014,350.00. Following the transaction, the executive vice president owned 191,021 shares in the company, valued at $178,469,010.09. This represents a 7.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Sanjay Mehrotra sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $968.90, for a total transaction of $38,756,000.00. Following the transaction, the chief executive officer directly owned 264,503 shares of the company’s stock, valued at $256,276,956.70. This represents a 13.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 124,424 shares of company stock valued at $116,629,966. 0.24% of the stock is currently owned by corporate insiders. Analyst Upgrades and Downgrades MU has been the topic of several research reports. TD Cowen restated a “buy” rating and issued a $1,600.00 target price on shares of Micron Technology in a research note on Thursday, October 1st. New Street Research upgraded shares of Micron Technology from a “neutral” rating to a “buy” rating and lifted their price target for the company from $470.00 to $1,250.00 in a report on Friday, August 14th. William Blair set a $1,300.00 target price on shares of Micron Technology in a report on Thursday, October 1st. Bank of America raised their price objective on shares of Micron Technology from $950.00 to $1,500.00 and gave the company a “buy” rating in a research note on Tuesday, June 23rd. Finally, Wolfe Research set a $1,500.00 price objective on Micron Technology in a report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, forty-one have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,407.88.

Get Our Latest Stock Analysis on Micron Technology

Micron Technology Trading Down 1.0% MU stock opened at $896.07 on Wednesday. Micron Technology, Inc. has a twelve month low of $192.40 and a twelve month high of $1,255.00. The company has a quick ratio of 2.94, a current ratio of 3.31 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 12.07, a price-to-earnings-growth ratio of 0.16 and a beta of 2.22. The firm’s fifty day simple moving average is $987.31 and its two-hundred day simple moving average is $872.76.

Micron Technology (NASDAQ:MU – Get Free Report) last released its quarterly earnings data on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $31.77 by $1.65. Micron Technology had a net margin of 63.80% and a return on equity of 92.62%. The company had revenue of $54.23 billion during the quarter, compared to analysts’ expectations of $51.33 billion. During the same period in the previous year, the company earned $3.03 EPS. The firm’s quarterly revenue was up 379.1% on a year-over-year basis. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. As a group, analysts anticipate that Micron Technology, Inc. will post 177.03 earnings per share for the current year.

Micron Technology Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 29th. Stockholders of record on Wednesday, October 14th will be issued a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a dividend yield of 0.1%. The ex-dividend date is Wednesday, October 14th. Micron Technology’s dividend payout ratio is currently 0.81%.

Micron Technology Profile (Free Report)

Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage products. Its portfolio includes dynamic random-access memory (DRAM), NAND flash memory, NOR flash memory, solid-state drives, memory modules, and other semiconductor solutions used in data centers, personal computers, smartphones, automotive systems, industrial equipment, and consumer electronics.

The company also provides high-bandwidth memory and other advanced memory technologies designed to support artificial intelligence, high-performance computing, networking, and graphics applications.

Featured Stories Five stocks we like better than Micron Technology Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding MU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Micron Technology, Inc. (NASDAQ:MU – Free Report).

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Kapitalo Investimentos Ltda lifted its position in shares of Micron Technology, Inc. (NASDAQ:MU – Free Report) by 2,644.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,442 shares of the semiconductor manufacturer’s stock after acquiring an additional 26,442 shares during the period. Micron Technology comprises approximately 2.1% of Kapitalo Investimentos Ltda’s holdings, making the stock its 9th largest holding. Kapitalo Investimentos Ltda’s holdings in Micron Technology were worth $29,229,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Denali Advisors LLC acquired a new position in Micron Technology during the 2nd quarter valued at about $7,364,000. Castleark Management LLC acquired a new stake in shares of Micron Technology in the first quarter valued at approximately $3,709,000. Oppenheimer & Co. Inc. increased its stake in shares of Micron Technology by 16.0% in the second quarter. Oppenheimer & Co. Inc. now owns 48,520 shares of the semiconductor manufacturer’s stock valued at $56,006,000 after purchasing an additional 6,702 shares during the period. Legacy Wealth Management LLC MS increased its stake in shares of Micron Technology by 73.3% in the second quarter. Legacy Wealth Management LLC MS now owns 3,544 shares of the semiconductor manufacturer’s stock valued at $4,091,000 after purchasing an additional 1,499 shares during the period. Finally, Franklin Street Advisors Inc. NC raised its holdings in shares of Micron Technology by 2,461.4% during the second quarter. Franklin Street Advisors Inc. NC now owns 37,141 shares of the semiconductor manufacturer’s stock valued at $42,871,000 after buying an additional 35,691 shares during the last quarter. 80.84% of the stock is currently owned by institutional investors.

Micron Technology Stock Down 1.0% MU stock opened at $896.07 on Wednesday. The firm’s 50-day moving average is $987.31 and its two-hundred day moving average is $872.76. The company has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 12.07, a price-to-earnings-growth ratio of 0.16 and a beta of 2.22. Micron Technology, Inc. has a 52 week low of $192.40 and a 52 week high of $1,255.00. The company has a current ratio of 3.31, a quick ratio of 2.94 and a debt-to-equity ratio of 0.03.

Micron Technology (NASDAQ:MU – Get Free Report) last posted its quarterly earnings data on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $31.77 by $1.65. The business had revenue of $54.23 billion during the quarter, compared to analysts’ expectations of $51.33 billion. Micron Technology had a net margin of 63.80% and a return on equity of 92.62%. The business’s revenue was up 379.1% on a year-over-year basis. During the same period last year, the firm posted $3.03 earnings per share. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. On average, analysts forecast that Micron Technology, Inc. will post 177.03 earnings per share for the current fiscal year. Micron Technology Announces Dividend The company also recently announced a quarterly dividend, which will be paid on Thursday, October 29th. Shareholders of record on Wednesday, October 14th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date is Wednesday, October 14th. Micron Technology’s dividend payout ratio is 0.81%.

Analysts Set New Price Targets Several equities analysts have recently issued reports on the company. HSBC boosted their price objective on Micron Technology from $1,100.00 to $1,700.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. The Goldman Sachs Group set a $1,250.00 target price on Micron Technology in a research report on Thursday, October 1st. Arete Research lifted their target price on Micron Technology from $852.00 to $1,500.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Morgan Stanley reaffirmed an “overweight” rating and set a $1,200.00 target price on shares of Micron Technology in a research note on Thursday, October 1st. Finally, JPMorgan Chase & Co. boosted their price target on Micron Technology from $550.00 to $1,540.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. One investment analyst has rated the stock with a Strong Buy rating, forty-one have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Micron Technology presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,407.88.

Read Our Latest Research Report on MU

Key Stories Impacting Micron Technology Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: Micron announced funding for Indium Corporation’s critical-minerals and high-purity materials processing expansion in New York. The investment, part of Micron’s planned U.S. supply-chain spending of up to $3 billion, is intended to improve access to materials needed for advanced memory production and reduce exposure to overseas supply disruptions. Micron Invests in New York Critical Minerals Processing With Indium Corporation Positive Sentiment: Bullish analysts continue to point to tight memory supply, rising contract prices, strong AI-related demand and a potential share repurchase program. Recent results and guidance also showed substantial revenue and earnings growth, supporting the view that Micron’s memory upcycle could extend through 2027 and beyond. Micron Stock Moves Higher: What’s Going On? Positive Sentiment: Some investors view MU as attractively valued relative to its earnings potential, with Wall Street highlighting its strong September-quarter performance, elevated memory prices and multiyear customer commitments as reasons for further upside. The Best Trillion-Dollar Stock to Buy Right Now, According to Wall Street Neutral Sentiment: Micron is scheduled to host a technology webinar on October 21, which could provide additional details on its AI-memory roadmap, manufacturing plans and demand outlook. Micron to Host Technology Webinar on Oct. 21 Negative Sentiment: A union at Micron’s Taoyuan facility in Taiwan plans to strike on October 22 over a bonus dispute. Because Taiwan is central to Micron’s DRAM production, investors are concerned about potential disruption, costs or shipment delays. Micron Union in Taiwan to Launch Strike Negative Sentiment: Memory stocks remain under pressure after a broader technology selloff revived fears that AI infrastructure spending and related valuations may be unsustainable. Investors are also questioning how long Micron’s unusually high profits can last as new capacity comes online and rivals respond. Micron Stock Falls Amid Three Warning Signals Negative Sentiment: China’s CXMT is progressing toward server-memory production, raising longer-term competitive and pricing concerns for Micron, particularly if Chinese suppliers expand despite export restrictions. Intel Versus Micron: Exposure to CXMT Insider Transactions at Micron Technology In other news, CEO Sanjay Mehrotra sold 40,000 shares of Micron Technology stock in a transaction on Friday, August 21st. The stock was sold at an average price of $968.90, for a total transaction of $38,756,000.00. Following the transaction, the chief executive officer directly owned 264,503 shares in the company, valued at approximately $256,276,956.70. This trade represents a 13.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Scott R. Allen sold 879 shares of Micron Technology stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $1,000.00, for a total value of $879,000.00. Following the transaction, the chief accounting officer owned 34,958 shares in the company, valued at approximately $34,958,000. This trade represents a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 124,424 shares of company stock valued at $116,629,966. 0.24% of the stock is currently owned by company insiders.

Micron Technology Profile (Free Report)

Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage products. Its portfolio includes dynamic random-access memory (DRAM), NAND flash memory, NOR flash memory, solid-state drives, memory modules, and other semiconductor solutions used in data centers, personal computers, smartphones, automotive systems, industrial equipment, and consumer electronics.

The company also provides high-bandwidth memory and other advanced memory technologies designed to support artificial intelligence, high-performance computing, networking, and graphics applications.

Recommended Stories Five stocks we like better than Micron Technology Aurora Rejects Curaleaf’s Higher Bid, But the Takeover Fight Isn’t Over Centrus Energy Is Building a Nuclear Fuel Powerhouse—Why Is Its Stock Struggling? Halliburton Gains Traction: Multiyear Upcycle Ahead Meta Platforms’ AI Comeback Faces an Earnings Test—And a $10 Billion Charge Want to see what other hedge funds are holding MU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Micron Technology, Inc. (NASDAQ:MU – Free Report).

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Micron (MU +0.02%) stock has more than tripled so far in 2026, making it the fourth-best-performing stock in the S&P 500 (^GSPC +0.21%) this year. That's an impressive run, but for investors, the past really doesn't matter; only the future.

So, could Micron repeat this feat in 2027? One metric suggests that the answer to that question is yes.

Image source: The Motley Fool.

The memory chip shortage is far from over
Micron produces memory chips, which have become some of the most in-demand tech hardware due to their scarcity. The companies that manufacture them were not ready for the massive growth in demand generated by the artificial intelligence (AI) build-out, which has consumed all the supplies they could produce this year.

Memory chips are essentially commodity products. When demand significantly outpaces supply, prices soar -- and that's exactly what happened this year. However, Micron's input costs barely shifted, so the rising prices it can now charge are pure profit, and the stock skyrocketed as investors watched the company's top and bottom lines multiply.

MU Micron Technology$896.26+$0.19 (+0.02%)

NASDAQ · As of 9:47 AM ET 10/21/26

Moreover, this shortage isn't going to end soon.

On the latest earnings call, Micron's management team advised investors that it expects conditions in the memory chip market to be even tighter in 2027 and 2028 than they were in 2026. But Micron has been building new foundry lines in the meantime, and with more production capacity coming online in 2027, it will be able to manufacture more chips to sell at these higher price points, leading to significant additional profit growth.

This is reflected in Wall Street's outlook for the stock. Micron reported $75.52 in earnings per share during its fiscal 2026 (which ended in August), and management estimates Micron will generate a jaw-dropping $176.55 in earnings per share during its fiscal 2027.

Over the past couple of years, Micron's stock has usually traded in the neighborhood of 20 times earnings. Right now, it's a dirt cheap 12 times earnings because the market does not believe that this boom will last. However, its management team, which has access to more information about the tech sector than most investors, has already told anyone who will listen that the conditions leading to high memory demand and insufficient supply aren't going anywhere. As a result, the stock looks undervalued.

MU PE Ratio data by YCharts.

If Micron only meets analysts' expectations for its fiscal 2027, then in order to trade at just 15 times earnings next fall, the stock would have to triple. If it trades at 20 times earnings at that point, then the stock will have quadrupled from here.

The market's bearishness about the long-term outlook for AI spending has investors leaving obvious money on the table when it comes to a stock like Micron. Now is the time to take advantage of that mistake and buy Micron stock on sale, as it has major upside potential.

Over the last year, memory chip manufacturers have benefited from extraordinary demand for artificial intelligence (AI). In particular, Micron Technology (MU +0.02%) has witnessed its market capitalization propel from just $53 billion at the start of the AI revolution to more than $1 trillion today.

MU Market Cap data by YCharts

Despite its historic rally, investors should not assume Micron's growth is finished. As AI moves beyond data centers and becomes increasingly embedded in everyday products, the company stands to benefit from another wave of demand. What's encouraging is that you don't need thousands of dollars to participate in Micron's upside.

As of this writing (Oct. 20), Micron stock trades around $900. But investors can purchase fractional shares, allowing them to invest a fixed amount without buying an entire share. Let's assess what could happen if you invested $150 in Micron every month between now and the end of 2030.

What tailwinds does Micron have? Micron manufactures DRAM, NAND flash memory, and high bandwidth memory (HBM). These products help computers process, access, and store information.

HBM is becoming particularly important because AI accelerators require vast amounts of memory to process queries efficiently. Micron is already shipping HBM4 products optimized for Nvidia's Vera Rubin architecture, positioning the company to benefit from the AI infrastructure build-out.

Importantly, Micron's long-run opportunity extends beyond Nvidia's GPUs. The proliferation of agentic AI, CPUs, robotics, and autonomous systems will create additional demand for memory and storage. As these applications become more sophisticated and move into production, they will inevitably require greater capacity to process information, store data, and handle complex workloads.

Consider the automotive industry as an example. Micron has already announced long-term supply agreements with General Motors and Ford Motor Company. These partnerships support next-generation vehicle platforms, including advanced driver-assistance systems and AI-powered experiences inside of cars.

Micron also forged agreements with automotive technology suppliers such as Qualcomm, DENSO, and Hyundai Mobis -- demonstrating how memory is becoming essential across applications beyond consumer devices and hyperscale data centers.

Image source: Micron Technology.

How big can Micron get? Micron currently boasts a market capitalization of roughly $1.03 trillion. I see a few reasons why the company could become significantly more valuable as AI infrastructure investments accelerate, fueling further demand for advanced memory.

First, AI systems are becoming more memory-intensive. As new processors enter production and companies deploy AI across enterprise applications, demand for HBM and advanced DRAM should continue growing.

Second, Micron is investing heavily in manufacturing capacity while securing longer-term strategic customer agreements. Higher-value products such as HBM should support more robust profitability than conventional DRAM, helping Micron turn growing demand into sustainable earnings growth.

Lastly, investors could begin valuing Micron differently as its role in the AI supply chain becomes more recognized and appreciated. Historically, memory manufacturers traded at modest valuation multiples because of their cyclical business models. However, increasingly sophisticated memory products, stickier customer relationships, and new use cases could support a more favorable long-term valuation.

Taken together, I think Micron could reach a $2.5 trillion market capitalization by December 2030. Compared with its current market cap, that represents 145% cumulative upside, equivalent to 24% annualized stock appreciation, or 1.8% per month when compounded.

While this is slightly aggressive, I think it's a reasonable upside scenario considering it's considerably below the stock returns Micron has already generated during the AI infrastructure supercycle. If I apply that projected growth rate to all 51 monthly investments of $150, the total contribution of $7,650 invested could finish 2030 worth approximately $12,400. That represents roughly $4,750 in investment gains, or 62% upside.

MU Micron Technology$896.26+$0.19 (+0.02%)

NASDAQ · As of 9:47 AM ET 10/21/26

Smart investors always think about the long term Of course, Micron's actual stock price won't move in a perfect line. Semiconductor stocks frequently experience sharp rallies and sell-offs, making short-term fluctuations difficult to predict. That's precisely what makes dollar-cost averaging appealing. Investors can build a position over a long-term time frame without attempting to identify the perfect entry price.

The bigger theme here is that Micron should continue benefiting from multiple secular growth tailwinds that can support additional stock price appreciation over the next several years. As AI becomes more integrated into computing, transportation, and everyday consumer products, demand for advanced memory should expand.

For this reason, I see Micron as a compelling buy-and-hold opportunity for patient investors right now.

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new product approvals , /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2026.

Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis. Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items. Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent1. Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55. In August, Abbott announced U.S. Food and Drug Administration (FDA) approval for Libre® Duo, the world's first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes. In August, Abbott announced that the company received CE Mark for its Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce the risk of stroke in patients with atrial fibrillation (AFib). In August, Abbott announced the launch of Similac® 360 Total Care® Made With Whole Milk —  the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the United States. In September, Abbott announced FDA approval for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver both pulsed field ablation (PFA) and radiofrequency (RF) energy to treat patients battling atrial fibrillation. In September, Abbott launched SimpleScreen™ CRC, an FDA-approved, blood-based colorectal cancer screening test for adults age 45 and older who are at average risk for the disease. "Abbott delivered strong third-quarter results, reflecting balanced growth across our portfolio," said Robert B. Ford, chairman and chief executive officer, Abbott. "With strong performance across multiple businesses and a robust pipeline of innovation, we are well-positioned to deliver sustainable growth in the years ahead."

THIRD-QUARTER BUSINESS OVERVIEW

Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

5,504

958

1,853

—

2,687

International

7,509

1,304

1,452

1,614

3,139

Total reported

13,013

2,262

3,305

1,614

5,826

% Change vs. 3Q25

U.S.

28.0

7.9

109.2

n/a

6.6

International

6.2

3.1

6.2

6.8

7.2

Total reported

14.5

5.1

46.7

6.8

6.9

Total reported excl. foreign exchange impact

14.8

4.9

46.6

8.4

7.4

Comparable sales growth

7.0

4.9

6.4

8.4

7.8

    U.S.

7.9

7.9

8.4

n/a

7.6

    International

6.4

2.8

4.0

8.4

8.0

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total Company

Nutrition

Diagnostics

Established
Pharmaceuticals

Medical Devices

U.S.

14,994

2,673

4,418

—

7,890

International

21,776

3,750

4,159

4,539

9,328

Total reported

36,770

6,423

8,577

4,539

17,218

% Change vs. 9M25

U.S.

17.7

(4.5)

72.0

n/a

7.1

International

8.2

1.1

6.3

9.3

11.7

Total reported

11.9

(1.3)

32.4

9.3

9.6

Total reported excl. foreign exchange impact

10.5

(2.1)

30.8

8.7

7.8

Comparable sales growth

5.2

(2.1)

3.8

8.7

8.2

    U.S.

4.7

(4.5)

4.9

n/a

8.1

    International

5.7

(0.3)

2.4

8.7

8.3

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Nutrition

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Pediatric

Adult

U.S.

958

577

381

International

1,304

486

818

Total reported

2,262

1,063

1,199

% Change vs. 3Q25

U.S.

7.9

11.0

3.5

International

3.1

6.4

1.3

Total reported

5.1

8.8

2.0

Total reported excl. foreign exchange impact

4.9

8.7

1.8

Comparable sales growth

4.9

8.7

1.8

    U.S.

7.9

11.0

3.5

    International

2.8

6.0

1.0

Worldwide Nutrition sales increased 5.1 percent on a reported basis and 4.9 percent on a comparable basis in the third quarter.

Worldwide Nutrition results were driven by broad-based growth across the portfolio, including sales growth of nearly 9.0 percent in Worldwide Pediatric.

On a sequential basis, Worldwide Nutrition sales increased $118 million compared to the second quarter of 2026.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Pediatric

Adult

U.S.

2,673

1,613

1,060

International

3,750

1,428

2,322

Total reported

6,423

3,041

3,382

% Change vs. 9M25

U.S.

(4.5)

(4.8)

(4.0)

International

1.1

3.7

(0.5)

Total reported

(1.3)

(1.0)

(1.6)

Total reported excl. foreign exchange impact

(2.1)

(1.6)

(2.6)

Comparable sales growth

(2.1)

(1.6)

(2.6)

    U.S.

(4.5)

(4.8)

(4.0)

    International

(0.3)

2.4

(2.0)

Diagnostics*

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

1,853

389

938

526

International

1,452

1,049

30

373

Total reported

3,305

1,438

968

899

% Change vs. 3Q25

U.S.

109.2

6.3

n/a

1.1

International

6.2

5.1

n/a

1.0

Total reported

46.7

5.4

n/a

1.1

Total reported excl. foreign exchange impact

46.6

5.4

n/a

0.9

Comparable sales growth

6.4

5.4

13.8

0.9

    U.S.

8.4

6.3

13.9

1.1

    International

4.0

5.1

12.1

0.7

Worldwide Diagnostics sales increased 46.7 percent on a reported basis and 6.4 percent on a comparable basis in the third quarter.

Worldwide Core Laboratory Diagnostics results were driven by balanced growth across major geographic regions including the U.S., Europe, Japan, and Latin America.

Cancer Diagnostics results were driven by growth of Cologuard® and also reflect contributions to growth from the precision oncology and international businesses.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Core Laboratory

Cancer Diagnostics

Rapid/Molecular
Diagnostics

U.S.

4,418

1,113

1,921

1,384

International

4,159

3,015

62

1,082

Total reported

8,577

4,128

1,983

2,466

% Change vs. 9M25

U.S.

72.0

6.1

n/a

(8.9)

International

6.3

5.8

n/a

1.9

Total reported

32.4

5.9

n/a

(4.5)

Total reported excl. foreign exchange impact

30.8

4.0

n/a

(5.4)

Comparable sales growth

3.8

4.0

13.5

(5.4)

    U.S.

4.9

6.1

13.5

(8.9)

    International

2.4

3.2

15.0

(0.4)

*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott's Cancer Diagnostics business.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Established Pharmaceuticals

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

1,614

1,195

419

Total reported

1,614

1,195

419

% Change vs. 3Q25

U.S.

n/a

n/a

n/a

International

6.8

9.0

1.1

Total reported

6.8

9.0

1.1

Total reported excl. foreign exchange impact

8.4

10.9

1.6

Comparable sales growth

8.4

10.9

1.6

    U.S.

n/a

n/a

n/a

    International

8.4

10.9

1.6

Established Pharmaceuticals sales increased 6.8 percent on a reported basis and 8.4 percent on a comparable basis in the third quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 9.0 percent on a reported basis and 10.9 percent on a comparable basis, led by double-digit growth in India and several markets across the Latin America and Asia Pacific regions.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Key Emerging
Markets

Other

U.S.

—

—

—

International

4,539

3,448

1,091

Total reported

4,539

3,448

1,091

% Change vs. 9M25

U.S.

n/a

n/a

n/a

International

9.3

10.5

5.6

Total reported

9.3

10.5

5.6

Total reported excl. foreign exchange impact

8.7

10.4

3.6

Comparable sales growth

8.7

10.4

3.6

    U.S.

n/a

n/a

n/a

    International

8.7

10.4

3.6

Medical Devices

Third Quarter 2026 Results (3Q26)

Sales 3Q26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

2,687

380

429

303

290

228

185

872

International

3,139

372

444

84

496

364

66

1,313

Total reported

5,826

752

873

387

786

592

251

2,185

% Change vs. 3Q25

U.S.

6.6

9.0

18.1

8.4

3.4

(11.1)

(5.6)

9.4

International

7.2

10.4

12.2

(2.7)

6.7

12.2

13.6

4.2

Total reported

6.9

9.7

15.0

5.8

5.4

1.9

(1.2)

6.2

Total reported excl. foreign exchange impact

7.4

10.0

15.5

6.0

5.7

2.6

(1.1)

6.7

Comparable sales growth

7.8

10.0

15.5

6.0

5.7

6.9

(1.1)

6.7

    U.S.

7.6

9.0

18.1

8.4

3.4

(2.3)

(5.6)

9.4

    International

8.0

11.0

13.1

(1.6)

7.1

13.5

13.9

4.9

Worldwide Medical Devices sales increased 6.9 percent on a reported basis and 7.8 percent on a comparable basis in the third quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors grew 7.3 percent on a reported basis and 7.7 percent on a comparable basis.

First Nine Months 2026 Results (9M26)

Sales 9M26 ($ in millions)

Total

Rhythm
Management

Electro-
physiology*

Heart
Failure

Vascular

Structural
Heart*

Neuro-
modulation

Diabetes
Care

U.S.

7,890

1,096

1,227

908

875

677

551

2,556

International

9,328

1,083

1,295

269

1,491

1,090

203

3,897

Total reported

17,218

2,179

2,522

1,177

2,366

1,767

754

6,453

% Change vs. 9M25

U.S.

7.1

10.4

16.0

10.2

5.2

(10.2)

(2.4)

9.3

International

11.7

13.9

14.5

7.9

8.0

16.1

18.1

10.5

Total reported

9.6

12.1

15.2

9.7

7.0

4.4

2.4

10.0

Total reported excl. foreign exchange impact

7.8

10.6

13.8

8.9

5.2

2.6

1.3

7.7

Comparable sales growth

8.2

10.6

13.8

8.9

5.2

6.5

1.3

7.7

    U.S.

8.1

10.4

16.0

10.2

5.2

(2.3)

(2.4)

9.3

    International

8.3

10.8

11.9

4.6

5.2

12.8

13.5

6.6

*Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 and $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.

Abbott's Financial Guidance
Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.50 to $5.55.

Abbott projects fourth-quarter 2026 adjusted diluted earnings per share of $1.62 to $1.67.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

Abbott Declares 411th Consecutive Quarterly Dividend
On Sept. 17, 2026, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Nov. 16, 2026, to shareholders of record at the close of business on Oct. 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott's Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million. Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

3Q25

% Change

Net Sales

$13,013

$11,369

14.5

Cost of products sold, excluding amortization expense

5,628

5,075

10.9

Amortization of intangible assets

841

420

n/m

Research and development

920

766

20.1

Selling, general, and administrative

4,266

3,051

39.8

Total Operating Cost and Expenses

11,655

9,312

25.2

Operating Earnings

1,358

2,057

(34.0)

Interest expense, net

297

44

n/m

Net foreign exchange (gain) loss

(6)

(17)

n/m

Other (income) expense, net

(164)

(150)

9.4

Earnings before taxes

1,231

2,180

(43.5)

Taxes on Earnings

311

536

(42.0)

1)

Net Earnings

$920

$1,644

(44.1)

Net Earnings excluding Specified Items, as described below

$2,477

$2,278

8.7

2)

Diluted Earnings per Common Share

$0.53

$0.94

(43.6)

Diluted Earnings per Common Share, excluding Specified Items, as described below

$1.42

$1.30

9.2

2)

Average Number of Common Shares Outstanding Plus Dilutive Common Stock
Options

1,738

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.557 billion, or $0.89 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $634 million, or $0.36 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

9M25

% Change

Net Sales

$36,770

$32,869

11.9

Cost of products sold, excluding amortization expense

15,843

14,397

10.0

Amortization of intangible assets

1,921

1,260

52.4

Research and development

2,579

2,207

16.9

Selling, general, and administrative

12,031

9,203

30.7

Total Operating Cost and Expenses

32,374

27,067

19.6

Operating Earnings

4,396

5,802

(24.2)

Interest expense, net

664

143

n/m

Net foreign exchange (gain) loss

(15)

(35)

n/m

Other (income) expense, net

(457)

(414)

10.2

Earnings before taxes

4,204

6,108

(31.2)

Taxes on earnings

1,279

1,360

(6.0)

1)

Net Earnings

$2,925

$4,748

(38.4)

Net Earnings excluding Specified Items, as described below

$6,789

$6,410

5.9

2)

Diluted Earnings per Common Share

$1.67

$2.70

(38.1)

Diluted Earnings per Common Share,

excluding Specified Items, as described below

$3.88

$3.65

6.3

2)

Average Number of Common Shares Outstanding

Plus Dilutive Common Stock Options

1,743

1,749

NOTES:

See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following section.

1)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 

2)

2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $3.864 billion, or $2.21 per share, for intangible amortization, legal settlements, acquisitions, restructuring actions, and other net expenses.

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.662 billion, or $0.95 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Third Quarter Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

3Q26

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      841

$      (841)

$        —

Gross Margin

6,544

904

7,448

R&D

920

(28)

892

SG&A

4,266

(761)

3,505

Other (income) expense, net

(164)

4

(160)

Earnings before taxes

1,231

1,689

2,920

Taxes on Earnings

311

132

443

Net Earnings

920

1,557

2,477

Diluted Earnings per Share

$     0.53

$     0.89

$      1.42

Specified items reflect intangible amortization expense of $841 million, legal settlements of approximately $670 million and other net expenses of $178 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

3Q25

As
Reported
(GAAP)

Specified
Items

As
Adjusted

Intangible Amortization

$      420

$     (420)

$        —

Gross Margin

5,874

470

6,344

R&D

766

(36)

730

SG&A

3,051

(47)

3,004

Other (income) expense, net

(150)

5

(145)

Earnings before taxes

2,180

548

2,728

Taxes on Earnings

536

(86)

450

Net Earnings

1,644

634

2,278

Diluted Earnings per Share

$     0.94

$      0.36

$      1.30

Specified items reflect intangible amortization expense of $420 million and other net expenses of $128 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries

Non-GAAP Reconciliation of Financial Information

Nine Months Ended September 30, 2026 and 2025

(in millions, except per share data)

(unaudited)

9M26

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$     1,921

$    (1,921)

$        —

Gross Margin

19,006

2,033

21,039

R&D

2,579

(77)

2,502

SG&A

12,031

(1,662)

10,369

Other (income) expense, net

(457)

(30)

(487)

Earnings before taxes

4,204

3,802

8,006

Taxes on Earnings

1,279

(62)

1,217

Net Earnings

2,925

3,864

6,789

Diluted Earnings per Share

$      1.67

$      2.21

$     3.88

Specified items reflect intangible amortization expense of $1.921 billion, legal settlements of approximately $1.070 billion and other net expenses of $811 million associated with acquisitions, restructuring actions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

9M25

As

Reported
(GAAP)

Specified
Items

As

Adjusted

Intangible Amortization

$    1,260

$   (1,260)

$        —

Gross Margin

17,212

1,396

18,608

R&D

2,207

(83)

2,124

SG&A

9,203

(58)

9,145

Other (income) expense, net

(414)

(31)

(445)

Earnings before taxes

6,108

1,568

7,676

Taxes on Earnings

1,360

(94)

1,266

Net Earnings

4,748

1,662

6,410

Diluted Earnings per Share

$     2.70

$      0.95

$     3.65

Specified items reflect intangible amortization expense of $1.260 billion and other net expenses of $308 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the third-quarter tax rates for 2026 and 2025 is shown below: 

3Q26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$     1,231

$       311

25.3 %

1)

Specified items

1,689

132

Excluding specified items

$    2,920

$      443

15.2 %

3Q25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    2,180

$      536

24.6 %

2)

Specified items

548

(86)

Excluding specified items

$    2,728

$      450

16.5 %

1)

2026 Taxes on Earnings includes the recognition of approximately $35 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

2)

2025 Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below: 

9M26

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$   4,204

$    1,279

30.4 %

3)

Specified items

3,802

(62)

Excluding specified items

$   8,006

$     1,217

15.2 %

9M25

($ in millions)

Pre-Tax

Income

Taxes on

Earnings

Tax

Rate

As reported (GAAP)

$    6,108

$    1,360

22.3 %

4)

Specified items

1,568

(94)

Excluding specified items

$    7,676

$    1,266

16.5 %

3)

2026 Taxes on Earnings includes the recognition of approximately $95 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

4)

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Third Quarter Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

3Q26

3Q25

% Change vs. 3Q25

Non-GAAP

Abbott
Reported

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

13,013

40

13,053

11,369

851

(23)

12,197

14.5

7.0

U.S.

5,504

—

5,504

4,299

824

(23)

5,100

28.0

7.9

Intl

7,509

40

7,549

7,070

27

—

7,097

6.2

6.4

Total Diagnostics

3,305

(2)

3,303

2,253

851

—

3,104

46.7

6.4

U.S.

1,853

—

1,853

886

824

—

1,710

109.2

8.4

Intl

1,452

(2)

1,450

1,367

27

—

1,394

6.2

4.0

Total Cancer Diagnostics

968

—

968

—

851

—

851

n/a

13.8

U.S.

938

—

938

—

824

—

824

n/a

13.9

Intl

30

—

30

—

27

—

27

n/a

12.1

Total Medical Devices

5,826

22

5,848

5,448

—

(23)

5,425

6.9

7.8

U.S.

2,687

—

2,687

2,521

—

(23)

2,498

6.6

7.6

Intl

3,139

22

3,161

2,927

—

—

2,927

7.2

8.0

Total Structural Heart*

592

4

596

580

—

(23)

557

1.9

6.9

U.S.

228

—

228

256

—

(23)

233

(11.1)

(2.3)

Intl

364

4

368

324

—

—

324

12.2

13.5

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the third quarter of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Non-GAAP Revenue Reconciliation

Nine Months Ended September 30, 2026 and 2025

($ in millions)

(unaudited)

9M26

9M25

% Change vs. 9M25

Non-GAAP

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Foreign
exchange

Comparable
Revenue

Abbott
Reported

Impact of
acquisition (a)

Impact

of multi-year
agreement (b)

Comparable
Revenue

Reported

Comparable

Total Company

36,770

706

(8)

(460)

37,008

32,869

2,369

(69)

35,169

11.9

5.2

U.S.

14,994

681

(8)

—

15,667

12,743

2,294

(69)

14,968

17.7

4.7

Intl

21,776

25

—

(460)

21,341

20,126

75

—

20,201

8.2

5.7

Total Diagnostics

8,577

706

—

(100)

9,183

6,480

2,369

—

8,849

32.4

3.8

U.S.

4,418

681

—

—

5,099

2,568

2,294

—

4,862

72.0

4.9

Intl

4,159

25

—

(100)

4,084

3,912

75

—

3,987

6.3

2.4

Total Cancer Diagnostics

1,983

706

—

(1)

2,688

—

2,369

—

2,369

n/a

13.5

U.S.

1,921

681

—

—

2,602

—

2,294

—

2,294

n/a

13.5

Intl

62

25

—

(1)

86

—

75

—

75

n/a

15.0

Total Medical Devices

17,218

—

(8)

(284)

16,926

15,712

—

(69)

15,643

9.6

8.2

U.S.

7,890

—

(8)

—

7,882

7,363

—

(69)

7,294

7.1

8.1

Intl

9,328

—

—

(284)

9,044

8,349

—

—

8,349

11.7

8.3

Total Structural Heart*

1,767

—

(8)

(31)

1,728

1,692

—

(69)

1,623

4.4

6.5

U.S.

677

—

(8)

—

669

753

—

(69)

684

(10.2)

(2.3)

Intl

1,090

—

—

(31)

1,059

939

—

—

939

16.1

12.8

*

Abbott's Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $156 million of sales in the first nine months of 2025 were moved from Structural Heart to Electrophysiology.

a)

The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.

b)

Reflects the impact of compensation payments that Abbott's Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          10

$             29

$         841

$           24

$        904

R&D

(7)

(5)

—

(16)

(28)

SG&A

(47)

(20)

—

(694)

(761)

Other (income) expense, net

(8)

(1)

—

13

4

Earnings before taxes

$           72

$             55

$         841

$          721

1,689

Taxes on Earnings (d)

132

Net Earnings

$      1,557

Diluted Earnings per Share

$        0.89

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the necrotizing enterocolitis (NEC) claims asserted on behalf of approximately 2,000 additional infants, as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Third Quarter Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$           —

$             44

$         420

$            6

$         470

R&D

—

(19)

—

(17)

(36)

SG&A

(9)

(43)

—

5

(47)

Other (income) expense, net

7

—

—

(2)

5

Earnings before taxes

$            2

$            106

$         420

$           20

548

Taxes on Earnings (d)

(86)

Net Earnings

$         634

Diluted Earnings per Share

$        0.36

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items. Taxes on Earnings includes approximately $160 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2026

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$          44

$             40

$        1,921

$           28

$       2,033

R&D

(18)

(15)

—

(44)

(77)

SG&A

(533)

(54)

—

(1,075)

(1,662)

Other (income) expense, net

(9)

(4)

—

(17)

(30)

Earnings before taxes

$         604

$             113

$        1,921

$        1,164

3,802

Taxes on Earnings (d)

(62)

Net Earnings

$       3,864

Diluted Earnings per Share

$         2.21

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.

c)

Other primarily includes approximately $670 million related to agreements entered into to resolve the Gill case and the NEC claims asserted on behalf of approximately 2,000 additional infants; approximately $400 million, including attorneys' fees and accrued interest, related to an agreement to resolve the United States Department of Justice (DOJ) investigations and the civil qui tam lawsuit brought by certain relators and joined by the DOJ and Attorneys General of several states; as well as incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $540 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

Abbott Laboratories and Subsidiaries

Details of Specified Items

Nine Months Ended September 30, 2025

(in millions, except per share data)

(unaudited)

Acquisition or
Divestiture-
related (a)

Restructuring
and Cost
Reduction
Initiatives (b)

Intangible
Amortization

Other (c)

Total
Specifieds

Gross Margin

$            1

$            125

$       1,260

$           10

$       1,396

R&D

(1)

(42)

—

(40)

(83)

SG&A

(15)

(49)

—

6

(58)

Other (income) expense, net

(18)

—

—

(13)

(31)

Earnings before taxes

$           35

$            216

$       1,260

$           57

1,568

Taxes on Earnings (d)

(94)

Net Earnings

$       1,662

Diluted Earnings per Share

$        0.95

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."

a)

Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.

b)

Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.

c)

Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.

d)

Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $460 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

SOURCE Abbott

PALO ALTO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Broadcom Inc. (NASDAQ: AVGO), a global technology leader that designs, develops, and supplies semiconductors and infrastructure software, today announced the launch of Arcot Scam Defense, a groundbreaking new feature of Arcot by Broadcom, designed to block social engineering fraud during card-not-present (CNP) transactions.

“Financial institutions are experiencing broad increases in fraud attempts driven by sophisticated, AI-enhanced social engineering attacks,” said Matt Cooke, vice president and general manager, Payment Security Division, Broadcom. “While technological security systems have advanced and are highly effective at blocking fraud, fraudsters have pivoted their efforts to hacking customers directly. By impersonating trusted brands and institutions, they trick cardholders into revealing passwords or completing step-up authentications. Cardholders usually remain unaware that they have handed over the keys to the castle until after the scam.”

How Social Engineering Works
During a payment flow, once a cardholder completes a 3-D Secure authentication challenge, by entering a one-time password (OTP) or using a biometric, the transaction is treated as legitimate and is approved by a financial institution’s primary risk models. While real-time risk assessment models are highly effective at flagging suspicious transactions, they are not designed to stop a legitimate account holder actively under the influence of a scam.

Introducing Arcot Scam Defense  
“Arcot Scam Defense closes a critical gap,” added Cooke. “It serves as the definitive safety net against social engineering attacks. Operating as a real-time second layer of defense, it leverages advanced intelligence during authentication to flag suspected fraud – even after a successful challenge. By closing the approval door on these attacks, we increase cardholder safety and drive down fraud losses, while continuing to allow legitimate transactions through.”

Arcot Scam Defense analyzes a broad range of signals across transaction information, device intelligence, historical behavior, and the challenge interaction itself to identify patterns indicative of social engineering. These can include discrepancies in the location and behavior of the transacting checkout device and the authenticating device, delayed OTP entry, the use of an alternative authentication method, or a significant physical distance between the two devices. These signals are evaluated collectively to inform a real-time decision rather than relying on any single indicator. Additionally, the solution can integrate with third-party solutions to determine if the authenticating device is on an active phone call, which is a prime indicator of social engineering.

Even if a cardholder falls for a scam and hands over their credentials, Broadcom’s Arcot Scam Defense feature can help identify the behavioral shift and block the transaction in real time.

The scale of the problem is immense, with nearly half a billion dollars in fraud reported over the last 12 months on successfully authenticated challenges. In pilot testing validated on a full month of live data, the Arcot Scam Defense feature demonstrated exceptional performance. For one major pilot issuer, reviewing just the top 1% of successful challenges would have protected an estimated $4 million in fraud in just a month, at a cost of only 0.38 points off their authentication success rate.

Looking ahead, Broadcom expects to expand Arcot Scam Defense’s capabilities by adding new signals, including cardholder and device attributes, and a dedicated challenge history profiling engine to learn each cardholder's past challenge behavior.

Arcot by Broadcom is exclusively focused on 3-D Secure payment authentication. For more information on how Arcot is redefining payment security, visit https://www.broadcom.com/products/software/payment-security.

About Broadcom
Broadcom Inc. (NASDAQ: AVGO) is a technology leader that designs, develops, and supplies semiconductors and infrastructure software for global organizations' complex, mission-critical needs. Broadcom combines long-term R&D investment with superb execution to deliver the best technology, at scale. Broadcom is a Delaware corporation headquartered in Palo Alto, CA. For more information, visit www.broadcom.com.

Broadcom, the pulse logo, and Connecting everything are among the trademarks of Broadcom. The term "Broadcom" refers to Broadcom Inc., and/or its subsidiaries. Other trademarks are the property of their respective owners.

Press Contact:

Eloy Ontiveros
Broadcom Global Communications
+1.650.427.6145
[email protected]

Key Takeaways Stryker gains FDA clearance for Sonopet 3, with first clinical cases set for October and a fall 2026 launch.SYK shares gained more than 2% since the Oct. 14 announcement, despite a 7.1% year-to-date decline.Sonopet 3's RISE integration and Pulse Control aim to boost surgical efficiency, precision and adoption.
Stryker (SYK - Free Report) recently received FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, the new system is designed to enhance surgical power, precision and workflow efficiency. The first clinical cases are expected to begin in October, with a full commercial launch anticipated later this fall.

The launch marks another step in Stryker’s efforts to strengthen its neurosurgical portfolio through product innovation and surgeon-focused technologies. The new platform could support customer engagement and create revenue growth opportunities as commercialization progresses. However, near-term financial contribution will likely depend on the pace of adoption, demand from hospitals and surgical centers, and the company's ability to translate the product's performance improvements into broader market penetration.

SYK Stock Trend Following the NewsFollowing the announcement on Oct. 14, SYK stock has gained more than 2% till yesterday’s close. Year to date, shares of the company have lost 13.4% compared with the industry’s 13.4% decline and the S&P 500’s 12% rise.

Stryker’s launch of Sonopet 3 could support its long-term growth by strengthening its neurosurgical portfolio and reinforcing its focus on surgeon-driven innovation. The platform’s enhanced power, precision and workflow integration could improve its appeal to surgeons and healthcare providers, supporting customer retention and adoption across surgical settings. Over time, successful commercialization could create incremental revenue opportunities and strengthen Stryker’s competitive positioning in the neurosurgery market.

SYK currently has a market capitalization of $108.02 billion.

Image Source: Zacks Investment Research

More on the NewsSonopet 3 was developed with feedback from hundreds of surgeons, with design improvements guided by their requirements for greater power, better ergonomics and enhanced integration in demanding surgical environments. The platform incorporates RISE, or Reimagined Integrated Surgical Experience, which is designed to support a more connected surgical workflow, and Pulse Control, which gives surgeons additional control over the removal of hard and soft tissues. These features are intended to improve usability and help streamline surgical workflows across different settings. According to Stryker, the enhancements reflect its focus on incorporating customer feedback into product development and advancing its neurosurgical technologies.

Stryker expects the first clinical cases using Sonopet 3 to begin in October, ahead of a full commercial launch anticipated later in fall 2026. The upcoming rollout will be an important step in gauging the platform's initial reception among surgeons and healthcare providers. Successful adoption could strengthen Stryker's competitive position in neurosurgery and create opportunities to deepen relationships with hospitals and surgical teams.

However, the company has not disclosed specific sales targets or the expected financial contribution from Sonopet 3. Its commercial impact will therefore depend on the pace of market adoption and the extent to which the new platform translates its performance and workflow enhancements into sustained customer demand.

Industry Prospects Favoring the MarketAccording to data provided by Persistence Market Research, the global neurosurgery market size is expected to be valued at $5.9 billion in 2026 and projected to reach $8.4 billion by 2033, expanding at a CAGR of 5.1% between 2026 and 2033.

The market is driven by the rise in global burden of neurological conditions, including traumatic brain injury, stroke, brain tumors and epilepsy, combined with rapid innovation in minimally invasive neurosurgical techniques, neuro-interventional devices and stereotactic radiosurgery systems.

Other NewsIn September, SYK announced an expansion of its Foot & Ankle portfolio, launching Prophecy Surgical Planning for the Incompass Total Ankle System and introducing Hoffmann LRF smartHEX at the 2026 American Orthopedic Foot & Ankle Society Annual Meeting. The new additions are designed to advance patient-specific surgical planning, implant flexibility and connected care across ankle replacement and limb reconstruction procedures.

SYK’s Zacks Rank & Key PicksCurrently, SYK carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are OPKO Health (OPK - Free Report) , Globus Medical (GMED - Free Report) and Merit Medical Systems (MMSI - Free Report) .

OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.

MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, with the average surprise being 14.1%.

COLUMBUS, Ohio, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Root, Inc. (NASDAQ: ROOT), the leading technology company in car insurance, today announced that Root Insurance is now available in Wyoming, expanding its auto insurance availability to 38 states representing 81% of the U.S. population. The launch of Root Insurance in Wyoming advances the company toward its goal of providing coverage across the contiguous United States by the end of 2027.

Wyoming drivers can now get a Root car insurance quote, customize their coverage, and purchase a policy in just minutes, and manage their policy directly in the Root app. Root uses technology and data science to more precisely understand and price risk while creating a simple, digital insurance experience for customers.

“Launching in Wyoming brings us another step closer to making Root available to drivers across the country,” said Alex Timm, Root Founder and CEO. “We’ve built a technology and data science platform that allows us to enter new markets efficiently and give more consumers access to a personalized, easy insurance experience. Wyoming drivers can now get a quote and purchase coverage whenever they're ready, making it possible to get insured and on the road the same day. We're excited to bring that experience to more drivers as we continue expanding nationwide.”

Root car insurance is now available in Wyoming
Wyoming drivers can now shop for, purchase, and manage Root auto insurance digitally. Root offers Wyoming customers the ability to:

Get a Root insurance quote and purchase coverage in minutes: Wyoming drivers can get a quote and purchase a policy online in just minutes.Customize their auto insurance coverage: Customers can select from available coverage limits and deductibles to find a policy that fits their individual needs.Manage their policy digitally: Root customers can access insurance documents, make policy changes, and start a claim through the Root mobile app.Access Root through multiple channels: Root offers insurance directly to consumers and through a growing network of independent insurance agents and distribution partners. Root offers personal auto insurance in Wyoming, including liability, comprehensive, and collision coverage, subject to eligibility and availability.

Car insurance coverage options available in Wyoming

Root offers Wyoming drivers a range of car insurance coverage options to meet their needs and protect them on the road. Available coverages include:

Liability Coverage: Helps pay for injuries and property damage you cause to others in an accident.Collision Coverage: Helps pay to repair or replace your vehicle if it's damaged in a collision, regardless of fault.Comprehensive Coverage: Helps cover damage to your vehicle from events outside of collisions, including theft, vandalism, severe weather, and falling objects.
Wyoming drivers can customize their policies by selecting available coverage options, limits, and deductibles that fit their needs and budgets. Coverage options are subject to eligibility and availability.

Root expands car insurance availability to 38 states
Wyoming is the 38th state where Root offers auto insurance, following the company's expansion into New Jersey in July 2026. With this latest launch, Root now offers car insurance in states representing 81% of the U.S. population and continues working toward its goal of expanding across the contiguous United States by the end of 2027.

Root was founded in 2015 in Columbus, Ohio, with a focus on using technology, data science, and driving behavior to improve how car insurance is priced and experienced. Its technology platform supports efficient geographic expansion and allows Root to reach customers through its direct-to-consumer channel, independent insurance agents, and distribution partners.

How to get Root car insurance in Wyoming

Wyoming drivers can get a quote and purchase coverage through the Root mobile app or by visiting the Wyoming car insurance page. Drivers can also start a quote online.

No test drive is required to purchase a Root policy in Wyoming. Eligible drivers can get a quote, select their coverage, and purchase insurance immediately through Root's digital experience.

Coverage, discounts, and eligibility may vary. Root auto insurance in Wyoming is underwritten by Root Property & Casualty Insurance Company.

Frequently Asked Questions About Root Insurance in Wyoming

Is Root Insurance available in Wyoming?
Yes. Root Insurance is now available in Wyoming. Wyoming is the 38th state where Root offers car insurance, expanding its availability to states representing 81% of the U.S. population.

Can I get Root car insurance immediately in Wyoming?
Yes. Wyoming drivers can get a Root car insurance quote and purchase coverage immediately, without completing a test drive or waiting for a driving evaluation. Eligible drivers can purchase a policy online in just minutes.

Does Root Insurance require a test drive?
No. Root Insurance does not require a test drive to purchase car insurance. Drivers can get a quote online, customize their coverage, and purchase a policy right away.

How much can you save with Root Insurance in Wyoming?
Safe drivers who switch to Root Insurance can save up to $1,300 annually, subject to driving behaviors and chosen coverage levels.*

*Potential annual savings based on survey of actual customers who purchased a new Root policy in active markets between February 2025 - February 2026 and reported savings; changes in coverage levels not evaluated. Potential savings will vary.

What types of car insurance coverage does Root offer in Wyoming?
Root offers personal auto insurance in Wyoming, including liability, comprehensive, and collision coverage, subject to eligibility and availability. Drivers can explore available coverage options at Root's Wyoming car insurance page.

How can I get a Root car insurance quote in Wyoming?
Wyoming drivers can get a quote and purchase coverage through the Root mobile app or by visiting the Wyoming car insurance page. Drivers can also start a quote online.

Can I buy and manage my Root car insurance online?
Yes. Root provides a digital insurance experience that allows customers to purchase and manage policies, access insurance documents, make policy changes, and start a claim through the Root mobile app.

Is Root Insurance available through independent insurance agents in Wyoming?
Root's availability through independent insurance agents in Wyoming is subject to confirmation. Agents interested in selling Root Insurance can apply, begin the process and get appointed in as little as 24 hours.

How many states does Root Insurance operate in?
Root now offers auto insurance in 38 states, including Wyoming, representing 81% of the U.S. population. The company plans to expand across the contiguous United States by the end of 2027.

Where is Root Insurance available?
Root offers car insurance in 38 states, including Wyoming. Consumers can check availability in their state and explore coverage options online.

About Root, Inc.
Root Insurance is a technology company revolutionizing car insurance through data science and automation. Founded in 2015 and based in Columbus, Ohio, Root, Inc. (NASDAQ: ROOT) is the parent company of Root Insurance Company. The Root app has reached more than 18 million downloads and has analyzed more than 37 billion miles of driving data to deliver personalized, easy, and fair pricing. Root is available in 38 states and offers auto insurance to consumers across the United States through its direct-to-consumer channel, independent insurance agents, and distribution partners.

For more information, visit root.com.

Contacts
Media:
[email protected]

Root Inc, Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws regarding Root, Inc. These forward-looking statements relate to, among other things, expectations about our future business results, the success of our business in Wyoming, and our ability to complete our expansion into the contiguous U.S. by year-end 2027. Such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the company's control and are difficult to predict. We have based our forward-looking statements on our current expectations, estimates, and projections about our industry and our company. We caution that these statements are not guarantees of future performance and you should not rely unduly on them, as they involve risks, uncertainties, and assumptions that we cannot predict. Accordingly, our actual results may differ materially from the future performance that we have expressed or forecast. In accordance with “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, we have included in Root's Form 10-K for the year ended Dec. 31, 2025, and other SEC filings, cautionary language identifying important factors that could cause future outcomes to differ materially from those set forth in the forward-looking statements. Copies of Root's Form 10-K and other SEC filings are available on the SEC's website, Root's website at ir.joinroot.com/investor-relations, or by contacting Root's Investor Relations office.

PJM assessment recognizes nearly all of FuelCell Energy’s installed capacity as dependable, an important proof point for reliability and potential capacity-market economics.  | Source: FuelCell Energy, Inc.

DANBURY, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL) announced that its FuelCell Energy Block System received a 99.873% rating in PJM Interconnection’s unit-specific Effective Load Carrying Capability (ELCC) assessment conducted as part of PJM’s 2028/29 Reliability Backstop Procurement (RBP) process. The result indicates that PJM may recognize nearly all of FuelCell Energy’s evaluated system’s capacity as dependable, providing an important measure of reliability for customers evaluating on-site power and informing potential participation in PJM’s capacity market.

Rapid data center growth is driving electricity demand and sharpening the focus on how large loads secure power. PJM projects 32 GW of peak load growth across its region from 2024 to 2030, with approximately 30 GW expected to come from data centers.1 As demand rises, large power users are increasingly considering generation that can provide dependable power where it is needed.

As communities hosting this growth place greater importance on how new electricity demand is met, FuelCell Energy’s carbonate fuel cell technology offers continuous, on-site generation that allows customers to locate power directly at the point of demand.

In practical terms, the 99.873% rating2 means PJM may count nearly 99.9 MW of every 100 MW evaluated as dependable capacity under the applicable assessment.

For context, preliminary PJM class ratings for the same 2028/2029 period recognize 96% of nuclear capacity, 93% of diesel utility/engine-based backup capacity and 67% of gas combustion turbine capacity.3

PJM’s unit specific assessment accredited 99.873% of the evaluated FuelCell Energy system’s capacity. PJM’s published technology class ratings provide a clear benchmark for the strength of that result. Following the Federal Energy Regulatory Commission's approval and delayed implementation of the Reliability Backstop Procurement (RBP), any future participation would be subject to PJM's applicable evaluation processes and could require updated accreditation using revised assumptions and study inputs for the final procurement timeline.

That reliability can have economic implications as well. For eligible projects in PJM, the amount of installed capacity recognized as dependable may affect the amount of capacity available for capacity-market participation and potential value, subject to applicable market requirements and auction or procurement outcomes.

“Customers aren’t simply looking for more megawatts. They need to understand how much power they can count on as they make decisions about where and how quickly they can grow,” said FuelCell Energy President & CEO Jason Few. “Our technology is designed to provide continuous, on-site distributed generation. This unit-specific assessment gives customers another independent measure of the dependability of our platform. It also has important economic implications: in PJM’s capacity market, the amount of installed capacity recognized as dependable directly influences the capacity a resource can potentially monetize. We believe a 99.873% accreditation highlights the potential for our platform to deliver not only highly dependable power, but attractive capital productivity for utilities and independent power producers deploying generation in PJM.”

Power That Counts

In addition to providing an independent measure of the evaluated system’s potential reliability contribution, capacity accreditation can have economic significance within PJM because it determines how much installed capacity is recognized as accredited capacity.

PJM uses ELCC to assess the reliability contribution of power resources and convert installed capacity (ICAP) into accredited capacity (UCAP). For eligible projects, higher accredited capacity may increase the amount of capacity available for capacity-market participation and potential value, subject to applicable market requirements and procurement or auction outcomes.

The 99.873% value is specific to the system evaluated for the 2028/2029 RBP process. It is not a FuelCell Energy technology-class rating or a measure of operating uptime, and future assessments may differ.

FuelCell Energy, Inc. (NASDAQ: FCEL) is an American clean energy technology company delivering continuous, scalable baseload power for mission-critical applications globally. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emissions power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems—backed by global fuel cell deployments approaching one gigawatt. Learn more at www.FuelCellEnergy.com. 

Contacts 

Media:                                                                                                                                                                        
Kathleen Blomquist 
[email protected] 
203.546.5844 

Investor Relations: 
[email protected]

_________________________

1 PJM Interconnection, “PJM Board Fast-Tracks Effort to Reliably Serve Large Loads,” PJM Inside Lines.
2 The 99.873% value is specific to the system evaluated for the 2028/2029 RBP process. It is not a FuelCell Energy technology-class rating or a measure of operating uptime, and future assessments may differ.
3 Preliminary ELCC Class Ratings for Use in the Reliability Procurement Backstop (RBP)

CareCredit Pay Later is CareCredit's enhanced installment loan product that will be presented digitally with CareCredit's revolving credit card to give consumers additional payment options and simplified offer comparisons.

Key Highlights:

Supporting providers and consumer choice: Offering more payment choices can help providers meet different consumer preferences, while CareCredit manages administrative and billing workflows.
One credit application. Two ways to pay: CareCredit Pay Later and the CareCredit credit card give eligible consumers two payment options to help manage care expenses.
Responsible credit access: Advanced underwriting through Synchrony PRISM evaluates overall active credit commitments to support responsible lending.
Payment predictability drives consumer decisions: 80% of surveyed consumers say payment options influence which provider they select, and 77% of consumers say having flexible payment options is critical when choosing a recommended treatment plan.
CareCredit stands apart: CareCredit is the only health and wellness financing platform and network that offers revolving credit, installment loans, promotional financing solutions, and broad provider acceptance across more than 290,000 healthcare locations nationwide.
, /PRNewswire/ -- CareCredit, a Synchrony (NYSE: SYF) solution, today launched CareCredit Pay Later, its enhanced and rebranded installment loan product that provides health and wellness consumers with a clear payment plan and defined payoff timeline to help budget for products and elective health and wellness expenses not covered by insurance. CareCredit Pay Later presents another option to CareCredit's existing credit card and offers another way for eligible consumers to plan and pay for care. It is available today at nearly 20,000 health and wellness locations, including select dental, cosmetic, vision, and audiology care providers, with expansion across CareCredit's entire network over time.

CareCredit Pay Later presents another option to CareCredit’s existing credit card and offers another way for eligible consumers to plan and pay for care. It is available today at nearly 20,000 health and wellness locations, including select dental, cosmetic, vision, and audiology care providers, with expansion across CareCredit’s entire network over time.

CareCredit Pay Later is CareCredit’s enhanced installment loan product that will be presented digitally with CareCredit’s revolving credit card to give consumers additional payment options and simplified offer comparisons.

Through a single credit application, eligible consumers can view the full array of CareCredit payment options available to them, so they can choose the product that best fits their budget, including:

CareCredit Pay Later: A one-time-use installment loan, offering fixed monthly payments, a clear payoff timeline, and a fixed APR for defined care expenses.
CareCredit Credit Card and CareCredit Rewards Mastercard®: Reusable revolving credit products that offer special financing options with convenient monthly payments, accepted across 290,000 locations nationwide, as well as select retailers, such as Albertson's, Walgreens and Walmart.

CareCredit Pay Later offers enhanced tools designed to make financing conversations even easier for providers and consumers. The payment calculator, available directly from the Provider Center portal homepage, now includes CareCredit Pay Later and uses each provider's specific promo mix to deliver more accurate estimated payment amounts. In addition, providers can now modify loan amounts before funding, creating greater flexibility to accommodate for treatment plan changes and helping ensure financing stays aligned with care decisions.

To ensure consumers are extended credit responsibly, CareCredit utilizes Synchrony PRISM®, Synchrony's proprietary underwriting platform. PRISM evaluates an applicant's broader financial health — looking beyond static credit scores to evaluate active lines of credit, debt-to-income indicators, and existing loan commitments that may not show on traditional credit reports. Consumers are encouraged to ask their participating CareCredit enrolled provider about the payment options that may be available to them, so they can make an informed decision. CareCredit Fair Financing Principles (FFP) initiative — designed to set a high standard for transparency and consumer education — connects consumers with product comparison guides, budgeting tools like CareCredit's procedure calculator, and an educational consumer guide managing commitments responsibly.

"In an industry where many treatments and products are elective, having flexible ways to pay for care is critical for consumers," said Adam Reinebach, CEO of the American Med Spa Association (AmSpa). "For med spa customers, having choices like the CareCredit credit card and CareCredit Pay Later can make it easier to move forward with the care they want, while benefiting from the confidence of paying through a trusted industry financing partner."

By providing tailored choices up front and allowing participating providers to easily customize promotions and then view, filter, and share available offers, this multi-product experience can help improve treatment conversion and acceptance, while CareCredit eases administrative burdens and helps simplify the payment process.

"When it comes to health and wellness, a 'one-size-fits-all' payment plan doesn't work for everyone," said Beto Casellas, Executive Vice President and Chief Executive Officer of Health & Wellness at Synchrony. "With CareCredit Pay Later, consumers now have more options to choose from based on their purchase, monthly budget, and preferences. By expanding these choices, we're empowering people to plan and pay for the care they want."

Research Shows Payment Clarity and Choice Matter When Planning and Paying for Care
The expanded offering comes as CareCredit consumer research reveals how strongly cost, payment clarity and choice can shape care experiences and decisions.

According to the research:

Cost clarity matters early. 58% of consumers worry about how much care will cost, and 51% say it's not always clear what out of pocket expenses will be.[1] In addition, 77% say knowing the total cost of care upfront is very or extremely important.1 
Payment experience can influence provider choice. 80% say payment options influence which provider they select,[2] and 50% would consider switching providers if billing became too cumbersome.1 
Credit access can help consumers move forward. 41% say they would likely postpone their care if they could not pay using credit, and 46% would postpone if they had to pay full price upfront.2
To learn more about CareCredit, visit https://www.carecredit.com/.

FAQ

What is CareCredit Pay Later?
CareCredit Pay Later is a single-use installment loan that offers eligible consumers a fixed APR, set monthly payments, and a defined payoff timeline to budget for specific health and wellness expenses.

How does Synchrony ensure CareCredit Pay Later is used responsibly? 
CareCredit utilizes Synchrony PRISM®, an advanced underwriting engine that looks at an applicant's complete financial picture. PRISM evaluates overall active debt commitments — including active loans across other platforms — to help ensure applicants are not taking on payments they cannot comfortably manage.

How is CareCredit Pay Later different from the CareCredit credit card?
CareCredit Pay Later is a single-use installment loan that closes once the balance is paid in full. The CareCredit credit card is a reusable line of credit offering deferred interest options and ongoing utility across more than 290,000 provider and retail locations nationwide.

How is CareCredit Pay Later different from Pay In Four?
CareCredit Pay Later offers consumers longer-term installment options with fixed monthly payments, a fixed APR, and defined payoff timelines designed to help budget for larger health and wellness expenses, whereas Pay in four plans typically split smaller purchases into four short-term, bi-weekly payments.

Will checking my eligibility impact my credit score?
No. Consumers can see if they prequalify for CareCredit financing options through a simple application with no hard credit check, meaning there is no impact to their credit score.

Where can I use CareCredit Pay Later?
CareCredit Pay Later is currently rolling out to nearly 20,000 participating health and wellness locations, including select dental, cosmetic, vision, and audiology providers, with planned expansions across CareCredit's network over time. Consumers are encouraged to ask their provider which CareCredit payment options are currently available at their practice.

Can I use a CareCredit Pay Later loan for multiple, ongoing treatments?
CareCredit Pay Later is designed as a single-use loan for a specific treatment, procedure, or purchase. For ongoing care wants and needs, elective care, and repeat use across our provider network, the CareCredit credit card remains an ideal reusable financing option.

How does offering CareCredit Pay Later benefit health and wellness providers and practices?
Because every consumer's financial situation is different, a "one-size-fits-all" approach to payments no longer works. By offering an expanded suite of payment options with a single application, providers can meet diverse consumer wants and needs and help more people say "yes" to recommended care. Furthermore, CareCredit manages all billing and collections, streamlining the payment experience for practice staff and protecting providers against payment delays and defaults.

About the Research
The findings cited in this release are drawn from two CareCredit consumer research studies: Well, Informed, which explored consumer attitudes and experiences related to healthcare costs and payment preferences, and Path to Purchase, which examined when and how payment information influences decisions across the healthcare journey. Respondents across both studies totaled 4,105. Additional methodological information is available upon request. 

About Synchrony
Synchrony (NYSE: SYF) is a leading consumer financing company that has been at the heart of American commerce and opportunity for nearly a century. Synchrony delivers credit and banking products that empower tens of millions of consumers to improve their financial lives and access what matters most. Leveraging innovative solutions that are shaping the future of retail commerce, Synchrony supports the growth and success of some of the nation's most respected brands, alongside hundreds of thousands of small and midsize businesses, including health and wellness providers. Committed to excellence in service and culture, Synchrony is honored to be ranked the #1 Best Company to Work For® in the U.S. by Fortune magazine and Great Place to Work®. For more information, visit www.synchrony.com.

Contact:
Michelle Romero
Synchrony
[email protected] 

*Mastercard and the circles design are registered trademarks of Mastercard International Incorporated.

_____________________________

1 

"Well Informed." CareCredit. May, 2026.

2

"2026 CareCredit Path to Purchase." CareCredit. March, 2026.

SOURCE Synchrony

FREMONT, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company, today confirmed that its IQ® EV Charger 2 supports the ISO 15118-20 communication standard required under the European Union's Alternative Fuels Infrastructure Regulation (AFIR). The requirement takes effect on Jan. 1, 2027.

Under AFIR, newly installed or renovated public and private EV chargers in the EU must support ISO 15118-20, the protocol that governs secure communication between vehicle and charger and enables features such as automatic authentication, so charging starts as soon as the car is plugged in, and bidirectional charging, where supported by the vehicle and the charging setup. IQ EV Charger 2 has supported the standard since launch, so distributors and installers can keep offering it as is, with no part number changes or inventory adjustments. Chargers already installed at customer sites require no action to support the AFIR standard.

“We want to recommend a charging solution our customers can rely on for years,” said Fedde Tjalsma, solar service manager at Mensonides Installatie, an installer of Enphase products in the Netherlands. “With ISO 15118 support, Enphase is preparing its chargers for vehicle-to-grid capabilities down the road. That forward-looking approach is a big plus for us as an installer.”

“What especially appeals to me as an installer about the Enphase IQ EV Charger 2 is that they clearly looked beyond just charging an electric car,” said Kick Vermeulen, owner of Kick Power, an installer of Enphase products in the Netherlands. “With its focus on new technologies and communication standards such as ISO 15118, Enphase shows that it develops solutions not only for today, but also for the energy world of tomorrow. That makes the IQ EV Charger 2 a future-proof choice for me.”

"Regulations will keep evolving, and our customers shouldn't have to chase them," said Jayant Somani, senior vice president of the digital business unit at Enphase Energy. "IQ EV Charger 2 was ready for ISO 15118-20 from day one. Installers can choose it with confidence, and we're inviting automakers to test with us so drivers can get the most out of their home energy."

Enphase plans to continue releasing over-the-air firmware updates to add new features and expand vehicle compatibility, so installers and homeowners can get more from the same hardware they put in on day one.

Distributors and installers can contact their Enphase sales representative to learn more about IQ EV Charger 2 compatibility with AFIR. For more information about the IQ EV Charger 2, please visit the regional websites (Netherlands, France, Germany, Norway). To access Enphase Energy’s self-declaration of compliance with AFIR, visit the Documentation section of the relevant product pages and open the document titled “ISO 15118-2 / ISO 15118-20 Protocol Support and Testing.”

About Enphase Energy, Inc.

Enphase Energy is a global energy technology company advancing intelligent power systems for homes, businesses, and next-generation AI data centers. The company designs semiconductor-based energy technologies spanning solar, batteries, EV charging, energy management, and virtual power plants, and is developing solid-state transformer technology to address the rapidly growing power demands of AI data centers. Based in Fremont, California, Enphase is the world’s leading supplier of microinverter-based solar and battery systems. The company revolutionized the solar industry with its microinverter technology and has shipped approximately 89.4 million microinverters, with approximately 5.3 million Enphase-based systems deployed in more than 165 countries. Enphase products enable people to harness the sun to make, use, save, and sell their own power, all controlled through the Enphase App. For more information, visit https://enphase.com/.

©2026 Enphase Energy, Inc. All rights reserved. Enphase Energy, Enphase, the “e” logo, IQ, and certain other marks listed at https://enphase.com/trademark-usage-guidelines are trademarks or service marks of Enphase Energy, Inc. Other names are for informational purposes and may be trademarks of their respective owners.

Forward-Looking Statements

This press release may contain forward-looking statements, including statements related to the expected capabilities and performance of Enphase Energy's IQ EV Charger 2, including safety, quality, reliability, and interoperability; the ability of IQ EV Charger 2 to support the ISO 15118-20 communication standard and comply with the requirements of the AFIR; Enphase Energy's plans to support additional vehicle interoperability and functionality through testing programs and over-the-air firmware updates; and the expected benefits of future software enhancements and expanded vehicle compatibility. These forward-looking statements are based on Enphase Energy's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. Such risks include, but are not limited to, market demand for EV charging solutions and related products; competitive developments; changes in electric vehicle adoption rates; changes in regulatory, certification, interoperability, or compliance requirements, including AFIR requirements; compatibility with third-party vehicles, energy systems, software platforms, and charging standards; product performance and reliability under actual operating conditions; supply chain availability and costs; and other factors discussed in Enphase Energy's filings with the Securities and Exchange Commission, including those risks described in more detail in Enphase Energy's most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other filings made from time to time with the Securities and Exchange Commission. Enphase Energy undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

Contact:

Enphase Energy
[email protected]

Hledat v komentářích

Investiční doporučení

Výsledky společností - ČR

Výsledky společností - Svět

IPO, M&A

Týdenní přehledy

Detail - články

21.10.2026 15:30

SAB Finance a.s.
IČ 247 17 444

Představenstvo společnosti SAB Finance a.s., IČO 247 17 444, se sídlem Na Příkopě 969/33, 110 00 Praha 1 – Staré Město, Česká republika, zapsané v obchodním rejstříku vedeném Městským soudem v Praze pod spis. zn. B 16383, v souvislosti s pověřením valné hromady ke zvýšení základního kapitálu upisováním nových akcií na majitele v zaknihované podobě ze dne 18. září 2026 uveřejňuje, že:

v rámci první fáze úpisu bylo upsáno 547.596 kusů akcií a do druhé fáze přechází 395.801 kusů akcií.

Zpráva je dostupná také na webu https://www.sab.cz/pro-investory#aktuality.

(komerční sdělení)

Tagy: Povinně uveřejňované informace
Reklama

Na tomto místě můžete zahájit diskusi. Zatím nebyl zadán žádný názor. Do diskuse mohou přispívat pouze přihlášení uživatelé (Přihlásit). Pokud nemáte účet, na který byste se mohli přihlásit, registrujte se zde.

Aktuální komentáře

21.10.2026 15:30SAB Finance a.s.: Veřejná nabídka nových akcií SAB Finance a.s. – druhá fáze úpisu 15:18CSG představila obojživelné vozidlo Meander. Novinka zvládne převézt až 70 vojáků 14:35SpaceX už není jen vesmírný příběh. Hlavním motorem růstu se stává AI   13:01Reklama se zadrhla, obsah tolik neláká a Netflix poprvé po letech hledá nový motor růstu   12:07Evropa obchoduje lehce v plusu, zatímco SpaceX zlepšila sentiment kolem polovodičů   11:55Getty Images požádala v USA o ochranu před věřiteli, zahájila restrukturalizaci 11:27PODCAST Rozhovory s Václavem Svátkem: AI je revoluce, ale investiční bublina může prasknout 10:11Anthropic by mohl za výpočetní výkon utratit až 750 miliard dolarů, v první polovině roku vykázal ztrátu přes 80 miliard 9:05Rozbřesk: Strach z dluhů AI firem změnilo chování hlavních trhů. Ale na jak dlouho? 8:49Optimismus vrací. Trhy podpořily výsledky SpaceX a Super Micro   8:27SpaceX překvapila rekordním ziskem. Musk poprvé veřejně připustil fúzi s Teslou 20.10.2026 22:29Netflix doručil tržby v souladu s očekáváním, ve zbytku roku ale očekává další zpomalení růstu 22:04Wall Street hledá pevnější půdu pod nohama. Rozhodnou výsledky a návratnost investic do AI   17:19Čekání na obrat v investičním boomu se nemusí vyplatit 16:17Plyn v Evropě zdražil nejvíce od roku 2022. Trh se obává nové energetické krize   15:29Facebook, TikTok i YouTube pod tlakem. Austrálie chystá žaloby kvůli porušování zákazu pro mladistvé 15:02Překonání odhadů ani oznámený zpětný odkup akcií nepomohl. Akcie GM po výsledcích klesají o sedm procent 13:31Fidelity: Kde hledat příležitosti mimo technologické giganty 12:07AMISTA investiční společnost, a.s.: TMR Fond SICAV a.s. - Pololetní finanční zpráva od 1. 1. 2026 do 30. 6. 2026 12:01Preview Mety: Trh zajímá monetizace AI a síla reklamního byznysu
Reklama

Související komentáře

Nejčtenější zprávy dne

Nejčtenější zprávy týdne

Nejdiskutovanější zprávy týdne

Kalendář událostí

Nebyla nalezena žádná data

Potřebujte poradit?